

(51) International Patent Classification:
C07D 501/00 (2006.01)(21) International Application Number:
PCT/US2009/056631(22) International Filing Date:
11 September 2009 (11.09.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/097,000 15 September 2008 (15.09.2008) US

(71) Applicant (for all designated States except US): ENANTA PHARMACEUTICALS, INC. [US/US]; 500 Arsenal Street, Watertown, MA 02472 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): QIU, Yao-ling [US/US]; 29 Linda Road, Andover, MA 01810 (US). WANG, Ce [CN/US]; 220 School Street, Suite 9, Waltham, MA 02451 (US). PENG, Xiaowen [CN/US]; 27 Shannon Street, #3, Brighton, MA 02135 (US). YING, Lu [CN/US]; 24 Wilson Ave., Belmont, MA 02478 (US). OR, Yat, Sun [US/US]; 169 Fayette Street, Watertown, MA 02472 (US).

(74) Agents: HARLAN, Edgar, W. et al.; ELMORE PATENT LAW GROUP, P.C., 515 Groton Rd., Unit 1R, Westford, MA 01886 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES



(57) **Abstract:** The present invention discloses compounds of formula (I), or its β -L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: Formula (I) which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.



4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES

RELATED APPLICATION

5 This application claims the benefit of U.S. Provisional Application No. 61/097,000, filed on September 15, 2008. The entire teachings of the above application are incorporated herein by reference.

TECHNICAL FIELD

10 The present invention relates generally to compounds and pharmaceutical compositions useful as antiviral and antiproliferative agents. Specifically, the present invention relates to nucleoside compounds with 4'-allenic substitution and methods for their preparation and use.

BACKGROUND OF THE INVENTION

15 Synthetic nucleosides such as 5-iodouracil and 5-fluorouracil have been used for the treatment of cancer for many years. Since the 1980's, synthetic nucleosides have also been a focus of interest for the treatment of HIV and hepatitis.

 In 1981, acquired immune deficiency syndrome (AIDS) was identified as a disease that severely compromises the human immune system, and that almost
20 without exception leads to death. In 1983, the etiological cause of AIDS was determined to be the human immunodeficiency virus (HIV). In 1985, it was reported that the synthetic nucleoside 3'-azido-3'-deoxythymidine (AZT) inhibits the replication of human immunodeficiency virus. Since then, a number of other synthetic nucleosides, including 2',3'-dideoxyinosine (DDI), 2',3'-dideoxycytidine (DDC), and 2',3'-dideoxy-2',3'-didehydrothymidine (D4T), have been proven to be
25 effective against HIV. After cellular phosphorylation to the 5'-triphosphate by cellular kinases, these synthetic nucleosides are incorporated into a growing strand of viral DNA, causing chain termination due to the absence of the 3'-hydroxyl group. They can also inhibit the viral enzyme reverse transcriptase.

30 The success of various synthetic nucleosides in inhibiting the replication of HIV in vivo or in vitro has led a number of researchers to design and test nucleosides that substitute a heteroatom for the carbon atom at the 3'-position of the nucleoside. European Patent Publication No. 0337713 and U.S. Pat. No. 5,041,449, assigned to BioChem Pharma, Inc., disclose 2-substituted-4-substituted-1,3-

dioxolanes that exhibit antiviral activity. U.S. Pat. No. 5,047,407 and European Patent Publication No. 0,382,526, also assigned to BioChem Pharma, Inc., disclose that a number of 2-substituted-5-substituted-1,3-oxathiolane nucleosides have antiviral activity, and specifically report that 2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (referred to below as BCH-189) has approximately the same activity against HIV as AZT, with little toxicity.

It has also been disclosed that cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane ("FTC") has potent HIV activity. Schinazi, et al., "Selective Inhibition of Human Immunodeficiency viruses by Racemates and Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolane-5-yl]-Cytosine" Antimicrobial Agents and Chemotherapy, November 1992, 2423-2431. See also U.S. Pat. No's. 5,210,085; 5,814,639; and 5,914,331.

Another virus that causes a serious human health problem is the hepatitis B virus (referred to below as "HBV"). HBV is second only to tobacco as a cause of human cancer. The mechanism by which HBV induces cancer is unknown. It is postulated that it may directly trigger tumor development, or indirectly trigger tumor development through chronic inflammation, cirrhosis, and cell regeneration associated with the infection.

After a two to six month incubation period in which the host is unaware of the infection, HBV infection can lead to acute hepatitis and liver damage, that causes abdominal pain, jaundice, and elevated blood levels of certain enzymes. HBV can cause fulminant hepatitis, a rapidly progressive, often fatal form of the disease in which massive sections of the liver are destroyed.

Patients typically recover from acute hepatitis. In some patients, however, high levels of viral antigen persist in the blood for an extended, or indefinite, period, causing a chronic infection. Chronic infections can lead to chronic persistent hepatitis. Patients infected with chronic persistent HBV are most common in developing countries. By mid-1991, there were approximately 225 million chronic carriers of HBV in Asia alone, and worldwide, almost 300 million carriers. Chronic persistent hepatitis can cause fatigue, cirrhosis of the liver, and hepatocellular carcinoma, a primary liver cancer.

In western industrialized countries, high risk groups for HBV infection include those in contact with HBV carriers or their blood samples. The epidemiology of HBV is very similar to that of acquired immune deficiency

syndrome, which accounts for why HBV infection is common among patients with AIDS or AIDS related complex. However, HBV is more contagious than HIV.

Both FTC and 3TC exhibit activity against HBV. Furman, et al., "The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (-) and (+) Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine" Antimicrobial Agents and Chemotherapy, December 1992, pp. 2686-2692; and Cheng, et al., Journal of Biological Chemistry, Volume 267(20), pp. 13938-13942 (1992). Other compounds that exhibit activity against HBV in humans include Clevudine or CLV (L-FMAU) (Pharmasset, Inc. under license from The University of Georgia Research Foundation and Yale University), and L-dT and L-dC (Idenix Pharmaceuticals, Inc.).

HCV is the major causative agent for post-transfusion and for sporadic non A, non B hepatitis (Alter, H. J. (1990) *J. Gastro. Hepatol.* 1:78-94; Dienstag, J. L. (1983) *Gastro* 85:439-462). Despite improved screening, HCV still accounts for at least 25% of the acute viral hepatitis in many countries (Alter, H. J. (1990) *supra*; Dienstag, J. L. (1983) *supra*; Alter M. J. *et al.* (1990a) *J.A.M.A.* 264:2231-2235; Alter M. J. *et al* (1992) *N. Engl. J. Med.* 327:1899-1905; Alter, M. J. *et al.* (1990b) *N. Engl. J. Med.* 321:1494-1500). Infection by HCV is insidious in a high proportion of chronically infected (and infectious) carriers who may not experience clinical symptoms for many years. The high rate of progression of acute infection to chronic infection (70-100%) and liver disease (>50%), its world-wide distribution and lack of a vaccine make HCV a significant cause of morbidity and mortality. Currently, there are three types of interferon and a combination of interferon and ribavirin used to treat hepatitis C. Selection of patients for treatment may be determined by biochemical, virologic, and when necessary, liver biopsy findings, rather than presence or absence of symptoms.

Interferon is given by injection, and may have a number of side effects including flu-like symptoms including headaches, fever, fatigue, loss of appetite, nausea, vomiting, depression and thinning of hair. It may also interfere with the production of white blood cells and platelets by depressing the bone marrow. Periodic blood tests are required to monitor blood cells and platelets. Ribavirin can cause sudden, severe anemia, and birth defects so women should avoid pregnancy while taking it and for 6 months following treatment. The severity and type of side effects differ for each individual. Treatment of children with HCV is not currently

approved but is under investigation. While 50-60% of patients respond to treatment initially, lasting clearance of the virus occurs in only about 10-40% of patients.

Treatment may be prolonged and given a second time to those who relapse after initial treatment. Re-treatment with bioengineered consensus interferon alone results
5 in elimination of the virus in 58% of patients treated for one year. Side effects occur but the medication is usually well tolerated. Combined therapy (interferon and ribavirin) shows elimination of the virus in 47% after 6 months of therapy. Side effects from both drugs may be prominent.

A tumor is an unregulated, disorganized proliferation of cell growth. A tumor
10 is malignant, or cancerous, if it has the properties of invasiveness and metastasis. Invasiveness refers to the tendency of a tumor to enter surrounding tissue, breaking through the basal laminae that define the boundaries of the tissues, thereby often entering the body's circulatory system. Metastasis refers to the tendency of a tumor to migrate to other areas of the body and establish areas of proliferation away from
15 the site of initial appearance.

Cancer is now the second leading cause of death in the United States. Over 8,000,000 persons in the United States have been diagnosed with cancer, with 1,208,000 new diagnoses expected in 1994. Over 500,000 people die annually from the disease in this country.

20 Cancer is not fully understood on the molecular level. It is known that exposure of a cell to a carcinogen such as certain viruses, certain chemicals, or radiation, leads to DNA alteration that inactivates a "suppressive" gene or activates an "oncogene." Suppressive genes are growth regulatory genes, which upon mutation, can no longer control cell growth. Oncogenes are initially normal genes
25 (called protooncogenes) that by mutation or altered context of expression become transforming genes. The products of transforming genes cause inappropriate cell growth. More than twenty different normal cellular genes can become oncogenes by genetic alteration. Transformed cells differ from normal cells in many ways, including cell morphology, cell-to-cell interactions, membrane content, cytoskeletal
30 structure, protein secretion, gene expression and mortality (transformed cells can grow indefinitely).

All of the various cell types of the body can be transformed into benign or malignant tumor cells. The most frequent tumor site is lung, followed by colorectal, breast, prostate, bladder, pancreas and then ovary. Other prevalent types of cancer

include leukemia, central nervous system cancers, including brain cancer, melanoma, lymphoma, erythroleukemia, uterine cancer, and head and neck cancer.

Cancer is now primarily treated with one or a combination of three means of therapies: surgery, radiation and chemotherapy. Surgery involves the bulk removal
5 of diseased tissue. While surgery is sometimes effective in removing tumors located at certain sites, for example, in the breast, colon and skin, it cannot be used in the treatment of tumors located in other areas, such as the backbone, or in the treatment of disseminated neoplastic conditions such as leukemia.

Chemotherapy involves the disruption of cell replication or cell metabolism.
10 It is used most often in the treatment of leukemia, as well as breast, lung, and testicular cancer.

There are five major classes of chemotherapeutic agents currently in use for the treatment of cancer: natural products and their derivatives; anthacyclines; alkylating agents; antiproliferatives (also called antimetabolites); and hormonal
15 agents. Chemotherapeutic agents are often referred to as antineoplastic agents.

The alkylating agents are believed to act by alkylating and cross-linking guanine and possibly other bases in DNA, arresting cell division. Typical alkylating agents include nitrogen mustards, ethyleneimine compounds, alkyl sulfates, cisplatin and various nitrosoureas. A disadvantage with these compounds is that they not only
20 attack malignant cells, but also other cells which are naturally dividing, such as those of bone marrow, skin, gastrointestinal mucosa, and fetal tissue.

Antimetabolites are typically reversible or irreversible enzyme inhibitors, or compounds that otherwise interfere with the replication, translation or transcription of nucleic acids.

25 Several synthetic nucleosides have been identified that exhibit anticancer activity. A well known nucleoside derivative with strong anticancer activity is 5-fluorouracil. 5-Fluorouracil has been used clinically in the treatment of malignant tumors, including, for example, carcinomas, sarcomas, skin cancer, cancer of the digestive organs, and breast cancer. 5-Fluorouracil, however, causes serious adverse
30 reactions such as nausea, alopecia, diarrhea, stomatitis, leukocytic thrombocytopenia, anorexia, pigmentation and edema. Derivatives of 5-fluorouracil with anti-cancer activity have been described in U.S. Pat. No. 4,336,381, and in Japanese patent publication No's. 50-50383, 50-50384, 50-64281, 51-146482, and 53-84981.

U.S. Pat. No. 4,000,137 discloses that the peroxidate oxidation product of inosine, adenosine or cytidine with methanol or ethanol has activity against lymphocytic leukemia.

Cytosine arabinoside (also referred to as Cytarabin, araC, and Cytosar) is a
5 nucleoside analog of deoxycytidine that was first synthesized in 1950 and introduced into clinical medicine in 1963. It is currently an important drug in the treatment of acute myeloid leukemia. It is also active against acute lymphocytic leukemia, and to a lesser extent, is useful in chronic myelocytic leukemia and non-Hodgkin's lymphoma. The primary action of araC is inhibition of nuclear DNA synthesis.
10 Handschumacher, R. and Cheng, Y., "Purine and Pyrimidine Antimetabolites" *Cancer Medicine, Chapter XV-1*, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers.

5-Azacytidine is a cytidine analog that is primarily used in the treatment of acute myelocytic leukemia and myelodysplastic syndrome.

15 2-Fluoroadenosine-5'-phosphate (Fludara, also referred to as FaraA) is one of the most active agents in the treatment of chronic lymphocytic leukemia. The compound acts by inhibiting DNA synthesis. Treatment of cells with F-araA is associated with the accumulation of cells at the G1/S phase boundary and in S phase; thus, it is a cell cycle S phase-specific drug. Incorporation of the active
20 metabolite, F-araATP, retards DNA chain elongation. F-araA is also a potent inhibitor of ribonucleotide reductase, the key enzyme responsible for the formation of dATP.

2-Chlorodeoxyadenosine is useful in the treatment of low grade B-cell neoplasms such as chronic lymphocytic leukemia, non-Hodgkins' lymphoma, and
25 hairy-cell leukemia.

In light of the fact that acquired immune deficiency syndrome, AIDS-related complex, hepatitis B virus and hepatitis C virus have reached epidemic levels worldwide, and have tragic effects on the infected patient, there remains a strong need to provide new effective pharmaceutical agents to treat these diseases that have
30 low toxicity to the host. Further, there is a need to provide new antiproliferative agents.

Therefore, it is an object of the present invention to provide a method and composition for the treatment of human patients or other host animals infected with HIV.

It is another object of the present invention to provide a method and composition for the treatment of human patients infected with hepatitis B or C.


It is a further object of the present invention to provide new antiproliferative agents.

- 5 It is still another object of the present invention to provide a new process for the preparation of 4'-allene-substituted nucleoside compounds of the present invention.

SUMMARY OF THE INVENTION

- 10 The present invention includes β -D and β -L-nucleoside compounds, pharmaceutical compositions comprising such compounds, as well as methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation comprising administering said compounds or compositions. In addition, the present invention includes the process for the preparation of such
- 15 compounds, and the related β -D and β -L-nucleoside derivatives.

The compounds of the invention are 4'-allene-substituted nucleoside compounds of the general formula (I):



- or their β -L enantiomers, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof, wherein:
- 20

X is selected from the group consisting of: O, S, Se, S(O), S(O)₂, CF₂, CHF, CH₂, C=CH₂, C=CHF, and C=CF₂;

- 25 R₁ is selected from the group consisting of:

- 1) hydrogen;
- 2) -CN;
- 3) halogen;
- 4) -N₃; and

- 30 5) Substituted or unsubstituted -C₁-C₈ alkyl;

R₂, R_{2a}, R₃ and R_{3a} are each independently selected from the group consisting of:

- 1) -C₁-C₈ alkyl, -C₂-C₈ alkenyl, -C₂-C₈ alkynyl or -C₃-C₈ cycloalkyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;
- 5 2) substituted -C₁-C₈ alkyl, substituted -C₂-C₈ alkenyl, substituted -C₂-C₈ alkynyl or substituted -C₃-C₈ cycloalkyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;
- 3) aryl or substituted aryl;
- 4) heteroaryl or substituted heteroaryl;
- 10 5) heterocyclic or substituted heterocyclic;
- 6) hydrogen;
- 7) -CN;
- 8) -NO₂;
- 9) halogen;
- 15 10) -N₃; and
- 11) -Y-R₁₁, wherein Y is O, S, or NR₁₂; and R₁₁ and R₁₂ are each independently selected from the group consisting of: hydrogen, hydroxy or amino protecting group, substituted or unsubstituted -C₁-C₈ alkyl, -CN, -C(O)R₁₄, -C(O)OR₁₃, and -C(O)NR₁₄R_{14a}; wherein R₁₃ is selected from the group
- 20 consisting of: substituted or unsubstituted -C₁-C₂₀ alkyl, substituted or unsubstituted -C₂-C₂₀ alkenyl, substituted or unsubstituted -C₂-C₂₀ alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclic or a group that is preferentially removed in a hepatocyte to yield the corresponding OH group; R₁₄ is
- 25 selected from the group consisting of: hydrogen and R₁₃; and R_{14a} is selected from the group consisting of: hydrogen, hydroxy and R₁₃; or alternatively R₁₁ and R₁₂ (in the case of Y = NR₁₂) or R₁₄ and R_{14a} taken together with the nitrogen atom to which they are attached form a heterocyclic ring;
- 30 or alternatively R₂ and R_{2a} or R₃ and R_{3a} taken together with the carbon atom to which they are attached form a group selected from:
 - 1) C=O;
 - 2) C=N-OR₁₄;

- 3) $C=CR_{15}R_{16}$, wherein R_{15} and R_{16} are each independently selected from the group consisting of: hydrogen, halogen, and substituted or unsubstituted $-C_1-C_8$ alkyl;
- 4) substituted or unsubstituted C_3-C_8 cycloalkyl; and
- 5) 3-7 membered heterocyclic ring containing at least one heteroatom selected from O, S or N;

or alternatively R_2 and R_3 or R_{2a} and R_{3a} taken together with the carbon atoms to which they are attached and the bond connecting these two carbon atoms form a group selected from:


- 1) a double bond;
- 2) substituted or unsubstituted C_3-C_8 cycloalkyl ring; and
- 3) 3-7 membered heterocyclic ring containing at least one heteroatom selected from O, S, P or N;
- Alternatively R_1 and R_2 or R_1 and R_{2a} taken together with the two carbon atoms to which they are attached and the bond connecting these two carbon atoms form a group selected from:
- 1) a double bond;
- 2) substituted or unsubstituted C_3-C_8 cycloalkyl ring; and
- 3) 3-7 membered heterocyclic ring containing at least one heteroatom selected from O, S or N;

R_{4a} , R_{4b} and R_{4c} are each independently selected from the group consisting of: hydrogen, halogen, and substituted or unsubstituted $-C_1-C_8$ alkyl;

L is $-CH_2-$ unless otherwise specified;

R_5 is $-Y-R_{11}$;

or alternatively L and R_5 taken together form a group of the following formula: $-L^1-L^2-L^3-P(=Y^1)W^1W^2$; wherein Y^1 is O or S; L^1 is $-CR_{15}R_{16}-$ or absent; and one of L^2 and L^3 is absent or $-O-$, $-S-$, $-NH-$, or $-CR_{15}R_{16}-$, and the other is independently $-CR_{15}R_{16}-$; and W^1 and W^2 are each independently $-Y^4-R^x$, $-Y^5-R^y$ or a group of the formula:



wherein:

Y^2 at each occurrence is independently O, S or NH;

Y^3 is absent, O, S, $-NR_{14}-$ or $-CR_{15}R_{16}-$;

5 Y^4 and Y^5 at each occurrence are each independently absent, O, S, or $-NR_{14}-$;

$M2$ is 0, 1 or 2;

R^x and R^y at each occurrence are each independently R_{14} ; or alternatively R^x and

R^y taken together with the atoms to which they are attached form a

heterocyclic ring or ring system, for example R^x and R^y taken together form

10 an optionally substituted, saturated or unsaturated C_2-C_8 alkylene group;

Alternatively W^1 or W^2 and R_3 or R_{3a} taken together form a linker group selected from O, S, or $-NR_{14}-$;

B is selected from a group consisting of: substituted or unsubstituted aryl,

15 substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclic; preferably a heterocycle containing at least one nitrogen atom.

In another embodiment, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound or

20 combination of compounds of the present invention, or a pharmaceutically acceptable salt form, prodrug, salt of a prodrug, stereoisomer, tautomer, solvate, or combination thereof, in combination with a pharmaceutically acceptable carrier or excipient.

In yet another embodiment, the present invention provides a method of

25 inhibiting the replication of an RNA or DNA containing virus comprising contacting said virus with a therapeutically effective amount of a compound or a combination of compounds of the present invention, or a pharmaceutically acceptable salt, prodrug, salt of a pro drug, stereoisomer, tautomer, solvate, or combination thereof.

Particularly, this invention is directed to methods of inhibiting the replication of

30 HIV, HBV and HCV.


In still another embodiment, the present invention provides a method of treating or preventing infection caused by an RNA or DNA-containing virus comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or combination of compounds of the present invention, or a pharmaceutically acceptable salt form, prodrug, salt of a prodrug, stereoisomer, or tautomer, solvate, or combination thereof. Particularly, this invention is directed to methods of treating or preventing infection caused by HIV, HBV and HCV.

Yet another embodiment of the present invention provides the use of a compound or combination of compounds of the present invention, or a therapeutically acceptable salt form, prodrug, salt of a prodrug, stereoisomer or tautomer, solvate, or combination thereof, as defined hereinafter, in the preparation of a medicament for the treatment or prevention of infection caused by RNA or DNA-containing virus, specifically HIV, HBV and HCV.

DETAILED DESCRIPTION OF THE INVENTION


One embodiment of the present invention is a compound of Formula (I) as illustrated above, or a pharmaceutically acceptable salt, ester or prodrug thereof.

An embodiment of the present invention is a 4'-allene-substituted nucleoside compound represented by formula (I) as illustrated above, or its β -L enantiomer (I-1), or pharmaceutically acceptable salt or prodrug thereof:



wherein R_1 , R_2 , R_{2a} , R_3 , R_{3a} , R_{4a} , R_{4b} , R_{4c} , R_5 , B, L and X are as previously defined.


An embodiment of the present invention is a β -D 4'-allene-substituted nucleoside compounds represented by formula (Ia), or its β -L enantiomer, or pharmaceutically acceptable salt or prodrug thereof:



wherein R_1 , R_2 , R_{2a} , R_3 , R_{3a} , R_{4a} , R_{4b} , R_{4c} , B and X are as previously defined.

Illustrative structures of formula (Ia) can be represented by formula (Iaa~Iax):


5



wherein B is as previously defined; and X^1 is O or S.


10

An embodiment of the present invention is a β -D 4'-allene-substituted nucleoside phosphate compounds represented by formula (Ib), or its β -L enantiomer, or pharmaceutically acceptable salt or prodrug thereof:



wherein R_1 , R_2 , R_{2a} , R_3 , R_{3a} , R_{4a} , R_{4b} , R_{4c} , B , X , R^x , R^y , Y^4 and Y^5 are as previously defined. Illustrative structures of formula (Ib) can be represented by formula

(Iba~Ibi):



5


wherein R_2 , R_{2a} , R_{3a} , B and X^1 are as previously defined; R_6 and R_7 are each independently hydrogen, phosphate, diphosphate, substituted or unsubstituted $-C_1$ - C_{20} alkyl, or a group that is preferentially removed in a hepatocyte to yield the corresponding OH group. The term "preferentially removed in a hepatocyte" as used

10 corresponding OH group. The term "preferentially removed in a hepatocyte" as used herein means at least part of the group is removed in a hepatocyte at a rate higher than the rate of removal of the same group in a non-hepatocytic cell (e.g., fibroblast or lymphocyte). It is therefore contemplated that the removable group includes all

15 pharmaceutically acceptable groups that can be removed by a reductase, esterase, cytochrome P450 or any other specific liver enzyme. Alternative contemplated groups may also include groups that are not necessarily preferentially removed in a hepatocyte, but effect at least some accumulation and/or specific delivery to a hepatocyte (e.g., esters with selected amino acids, including valine, leucine,

20 isoleucine, or polyarginine or polyaspartate).







An embodiment of the present invention is a β -D 4'-allene-substituted nucleoside phosphonate compound represented by formula (Ic), or its β -L enantiomer, or pharmaceutically acceptable salt or prodrug thereof:



5

wherein R_1 , R_2 , R_{2a} , R_3 , R_{3a} , R_{4a} , R_{4b} , R_{4c} , R_{15} , R_{16} , B , X , L^1 , R^x , R^y , Y^4 and Y^5 are as previously defined; and L^4 is absent or $-O-$, $-S-$, $-NH-$, or $-CR_{15}R_{16}-$.

Illustrative structures of formula (Ic) can be represented by formula (Ica~Icf):





10

wherein R_2 , R_{2a} , R_{3a} , B , X^1 , R^x , R^y , Y^4 and Y^5 are as previously defined.

In yet another particular embodiment of the present invention is a β -D 4'-allene-substituted nucleoside compound represented by formula (I), or its β -L enantiomer, or pharmaceutically acceptable salt or prodrug thereof, with B at each occurrence is an optionally substituted aryl, heteroaryl, or heterocyclic; preferably a heterocycle moiety containing at least one nitrogen, most preferably a pyrimidinyl, purinyl group or the like of the general formula of (B1)-(B2):

15




wherein:


R is selected from a group consisting of: O, S, NR_{14a}, NC(O)R_{14a}, NC(O)OR₁₄ and NC(O)NR₁₄R_{14a};

- 5 T, U, V and W are each independently N or CR₁₇; wherein R₁₇ is selected from a group consisting of: hydrogen, halogen, -CN, -C(O)R₁₄, -C(O)NR₁₄R_{14a}, -NO₂, -N₃, -OR₁₄, -SR₁₄, -NR₁₄R_{14a}, -OC(O)R₁₄, -OC(O)OR₁₄, -NHC(O)R_{14a}, -NHC(O)OR₁₄ and -NHC(O)NR₁₄R_{14a}, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic, substituted or unsubstituted -C₁-C₈ alkyl, substituted or unsubstituted -C₂-C₈ alkenyl, substituted or unsubstituted -C₂-C₈ alkynyl;

- 10 R²⁰, R²¹ and R²² are each independently selected from a group consisting of: hydrogen, halogen, -CN, -C(O)R₁₄, -C(O)NR₁₄R_{14a}, -NO₂, -N₃, -OR₁₄, -SR₁₄, -NR₁₄R_{14a}, -OC(O)R₁₄, -OC(O)OR₁₄, -NHC(O)R_{14a}, -NHC(O)OR₁₄ and -NHC(O)NR₁₄R_{14a}, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic, substituted or unsubstituted -C₁-C₈ alkyl, substituted or unsubstituted -C₂-C₈ alkenyl, substituted or unsubstituted -C₂-C₈ alkynyl.

- 20 Illustrative structures of B can be represented by formula (B1a~B1r), (B2a~B2o), and (B3a~B3j):





wherein R_{14} , R_{17} , R^{20} , R^{21} and R^{22} are as previously defined; and R_{18} is independently R_{17} .

- 5 In one embodiment of the invention, the 4'-allene-substituted nucleoside compounds of the invention are the isolated β -D or β -L isomer. In another embodiment of the invention, the nucleoside compound is in an enantiomeric mixture in which the desired enantiomer is at least 95%, 98% or 99% free of its enantiomer. In a preferred embodiment, the nucleoside compounds are
- 10 enantiomerically enriched.

In one embodiment of the present invention, the compounds of the formula (I) are in the β -D configuration. In an alternate embodiment of the present invention, the compounds of formula (I) are in the β -L configuration.

- The nucleoside compounds depicted above are in the β -D configuration,
- 15 however, it should be understood that the nucleoside compounds can be either in the β -L or β -D configuration.

- The nucleoside compounds of the present invention are biologically active molecules that are useful in the treatment or prophylaxis of viral infections, and in particular human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV)
- 20 infection. The compounds are also useful for the treatment of abnormal cellular proliferation, including tumors and cancer. In another embodiment of the present invention, any of the compounds are useful in the treatment of HCV. One can easily determine the spectrum of activity by evaluating the compound in the assays described herein or with another confirmatory assay.

For instance, in one embodiment the efficacy of the antiviral compound is measured according to the concentration of compound necessary to reduce the plaque number of the virus in vitro, according to methods set forth more particularly herein, by 50% (i.e. the compound's EC₅₀). In preferred embodiments the compound
5 exhibits an EC₅₀ of less than 15 or preferably, less than 10 micromolar in vitro.

In another embodiment, for the treatment or prophylaxis of a viral infection, and in particular an HIV, HCV or HBV infection, in a host, the compound or its derivative or salt can be administered in combination or alternation with another antiviral agent, such as an anti-HIV agent or anti-hepatitis agent, including those of
10 the formula above. Alternatively, for the treatment of abnormal cellular proliferation, such as tumors and cancer, in a host, the compound or its derivative or salt can be administered in combination or alternation with another antiproliferative agent, such as an anti-neoplastic agent, including those of the formula above. In general, in combination therapy, effective dosages of two or more agents are
15 administered together, whereas during alternation therapy, an effective dosage of each agent is administered serially. The dosages will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those skilled in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular
20 subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.

The compounds of the present invention can also be used to treat equine infectious anemia virus (EIAV), feline immunodeficiency virus, and simian
25 immunodeficiency virus. (Wang, S., et al, "Activity of nucleoside and non-nucleoside reverse transcriptase inhibitors (NNRTI) against equine infectious anemia virus (EIAV)."*First National Conference on Human Retroviruses and Related Infections*, Washington, D.C., Dec. 12-16, 1993; Sellon D. C., "Equine Infectious Anemia" *Vet. Clin. North Am. Equine Pract. United States*, 9: 321-336, 1993;
30 Philpott, M. S., et al "Evaluation of 9-(2-phosphonylmethoxyethyl)adenine therapy for feline immunodeficiency virus using a quantitative polymerase chain reaction" *Vet. Immunol. Immunopathol.* 35:155166, 1992).

The present invention also provides a pharmaceutical composition for the treatment and/or prophylaxis of a viral infection, and in particular a HBV, HCV or

HIV infection, in a host, preferably a human, comprising a therapeutically effective amount of a compound of the present invention, optionally in a pharmaceutically acceptable carrier.

5 The present invention also provides a pharmaceutical composition for the treatment and/or prophylaxis of an abnormal cellular proliferation, such as tumors and cancer, in a host, preferably a human, comprising a therapeutically effective amount of a compound of the present invention, optionally in a pharmaceutically acceptable carrier.

10 The present invention also provides a pharmaceutical composition for the treatment and/or prophylaxis of a viral infection, and in particular a HBV, HCV or HIV infection, in a host, preferably a human, comprising a therapeutically effective amount of a compound of the present invention, in combination with one or more other effective antiviral agent, and in particular an anti-HBV, anti-HCV or anti-HIV agent, optionally in a pharmaceutically acceptable carrier.

15 The present invention also provides a pharmaceutical composition for the treatment and/or prophylaxis of an abnormal cellular proliferation, such as tumors and cancer, in a host, preferably a human, comprising a therapeutically effective amount of a compound of the present invention, in combination with one or more other effective antinroliferative agent, such as an antineoplastic agent, optionally in a pharmaceutically acceptable carrier.

20 The present invention also provides a method for the treatment and/or prophylaxis of a viral infection, and in particular a HBV, HCV or HIV infection, in a host, preferably a human, comprising administering to the host a therapeutically effective amount of a compound of the present invention, optionally in a pharmaceutically acceptable carrier.

25 The present invention also provides a method for the treatment and/or prophylaxis of an abnormal cellular proliferation, such as tumors and cancer, in a host, preferably a human, comprising administering to the host a therapeutically effective amount of a compound of the present invention, optionally in a pharmaceutically acceptable carrier.

30 The present invention also provides a method for the treatment and/or prophylaxis of a viral infection, and in particular a HBV, HCV or HIV infection, in a host, preferably a human, comprising administering to the host a therapeutically effective amount of a compound of the present invention, in combination and/or

alternation with one or more other effective antiviral agent, and in particular an anti-HBV, anti-HCV or anti-HIV agent, optionally in a pharmaceutically acceptable carrier.

5 The present invention also provides a method for the treatment and/or prophylaxis of an abnormal cellular proliferation, such as tumors and cancer, in a host, preferably a human, comprising administering to the host a therapeutically effective amount of a compound of the present invention, in combination and/or alternation with one or more other effective antiproliferative agent, such as an antineoplastic agent, optionally in a pharmaceutically acceptable carrier.

10 The present invention also provides a use of a compound of the present invention, optionally in a pharmaceutically acceptable carrier, for the treatment and/or prophylaxis of a viral infection, and in particular a HBV, HCV or HIV infection, in a host, preferably a human.

15 The present invention also provides a use of a compound of the present invention, optionally in a pharmaceutically acceptable carrier, for the treatment and/or prophylaxis of an abnormal cellular proliferation, such as tumors and cancer, in a host, preferably a human.

20 The present invention also provides a use of a compound of the present invention, in combination and/or alternation with one or more other effective antiviral agent, and in particular an anti-HBV, anti-HCV or anti-HIV agent, optionally in a pharmaceutically acceptable carrier, for the treatment and/or prophylaxis of a viral infection, and in particular a HBV, HCV or HIV infection, in a host, preferably a human.

25 The present invention also provides a use of a compound of the present invention, in combination and/or alternation with one or more other effective antiproliferative agent, such as an antineoplastic agent, optionally in a pharmaceutically acceptable carrier, for the treatment and/or prophylaxis of an abnormal cellular proliferation, such as tumors and cancer, in a host, preferably a human.

30 The present invention also provides a use of a compound of the present invention, optionally in a pharmaceutically acceptable carrier, in the manufacture of a medicament for the treatment and/or prophylaxis of a viral infection, and in particular a HBV, HCV or HIV infection, in a host, preferably a human.

The present invention also provides a use of a compound of the present invention, optionally in a pharmaceutically acceptable carrier, in the manufacture of a medicament for the treatment and/or prophylaxis of an abnormal cellular proliferation, such as tumors and cancer, in a host, preferably a human.

5 The present invention also provides a use of a compound of the present invention, in combination and/or alternation with one or more other effective antiviral agent, and in particular an anti-HBV, anti-HCV or anti-HIV agent, optionally in a pharmaceutically acceptable carrier, in the manufacture of a medicament for the treatment and/or prophylaxis of a viral infection, and in
10 particular a HBV, HCV or HIV infection, in a host, preferably a human.

 The present invention also provides a use of a compound of the present invention, in combination and/or alternation with one or more other effective antiproliferative agent, such as an antineoplastic agent, optionally in a pharmaceutically acceptable carrier, in the manufacture of a medicament for the
15 treatment and/or prophylaxis of an abnormal cellular proliferation, such as tumors and cancer, in a host, preferably a human.

 The invention also provides synthetic methods useful for preparing the compounds of the invention, as well as intermediates disclosed herein that are useful in the preparation of the compounds of the present invention.

20 The invention as disclosed herein is method and composition for the treatment of HIV, hepatitis B or C, or abnormal cellular proliferation, in humans or other host animals, that includes administering a therapeutically effective amount of a β -D- or β -L-nucleoside compound, a pharmaceutically acceptable derivative, including a compound which has been alkylated or acylated on sugar or phosphonate
25 moiety, or on the purine or pyrimidine, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier. The compounds of this invention either possess antiviral (i.e., anti-HIV-1, anti-HIV-2, anti-hepatitis B/C virus) activity or antiproliferative activity, or are metabolized to a compound that exhibits such activity. The invention as disclosed herein also includes the process for the
30 preparation of such β -D- or β -L-nucleoside derivatives.

 Representative compounds of the present invention are those selected from: Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_{2a} = R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = 3$ -methoxycarbonyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl.

Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_{2a} = R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = \text{uracil-1-yl}$.

Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_{2a} = R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = \text{cytosine-1-yl}$.

- 5 Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_{2a} = R_{3a} = R_5 = OH$, $X = O$, $L = CH_2$, $B = \text{cytosine-1-yl}$.

Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_{2a} = R_{3a} = R_5 = OH$, $X = O$, $L = CH_2$, $B = \text{uracil-1-yl}$.

- 10 Compound of Formula (Ib), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_{2a} = R_{3a} = OH$, $R_5 = -OP(O)(OPh)(NHCHMeCO_2Me)$, $X = O$, $L = CH_2$, $B = \text{uracil-1-yl}$.

Compound of Formula (I), wherein $R_1 = R_{2a} = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = F$, $R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = 3\text{-methoxycarbonyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl}$.

- 15 Compound of Formula (I), wherein $R_1 = R_{2a} = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = F$, $R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = \text{uracil-1-yl}$.

Compound of Formula (I), wherein $R_1 = R_{2a} = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = F$, $R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = \text{cytosine-1-yl}$.

Compound of Formula (I), wherein $R_1 = R_{2a} = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = F$, $R_{3a} = R_5 = OH$, $X = O$, $L = CH_2$, $B = \text{cytosine-1-yl}$.

- 20 Compound of Formula (I), wherein $R_1 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = R_{2a} = F$, $R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = 3\text{-methoxycarbonyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl}$.

Compound of Formula (I), wherein $R_1 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = R_{2a} = F$, $R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = \text{uracil-1-yl}$.

- 25 Compound of Formula (I), wherein $R_1 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = R_{2a} = F$, $R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = \text{cytosine-1-yl}$.

Compound of Formula (I), wherein $R_1 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = R_{2a} = F$, $R_{3a} = R_5 = OH$, $X = O$, $L = CH_2$, $B = \text{cytosine-1-yl}$.

30 STEREOISOMERISM AND POLYMORPHISM

The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, individual diastereomers or enantiomers, with all isomeric forms being included in the present invention. Compounds of the present invention having a chiral center may exist in and be isolated in optically

active and racemic forms. Some compounds may exhibit polymorphism. The present invention encompasses racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein. Optically active forms of the compounds can be prepared using any method known in the art, including but not limited to by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials; by chiral synthesis, or by chromatographic separation using a chiral stationary phase or by enzymatic resolution.

10 DEFINITIONS

Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.

15 The term "aryl," as used herein, refers to a mono- or polycyclic carbocyclic ring system including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl.

The term "heteroaryl," as used herein, refers to a mono- or polycyclic aromatic radical having one or more ring atom selected from S, O and N; and the remaining ring atoms are carbon, wherein any N or S contained within the ring may be optionally oxidized. Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxalinyl.

25 In accordance with the invention, any of the aryls, substituted aryls, heteroaryls and substituted heteroaryls described herein, can be any aromatic group. Aromatic groups can be substituted or unsubstituted.

The terms "C₁-C₈ alkyl," or "C₁-C₂₀ alkyl," as used herein, refer to saturated, straight- or branched-chain hydrocarbon radicals containing between one and eight, or one and twelve carbon atoms, respectively. Examples of C₁-C₈ alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, *n*-butyl, *tert*-butyl, neopentyl, *n*-hexyl, heptyl and octyl radicals; and examples of C₁-C₁₂ alkyl radicals include, but are not limited to, ethyl, propyl, isopropyl, *n*-hexyl, octyl, decyl, dodecyl radicals.

The term "C₂-C₈ alkenyl," or "C₂-C₂₀ alkenyl," as used herein, refer to straight- or branched-chain hydrocarbon radicals containing from two to eight carbon atoms having at least one carbon-carbon double bond by the removal of a single hydrogen atom. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, heptenyl, octenyl, and the like.

The term "C₂-C₈ alkynyl," or "C₂-C₂₀ alkynyl," as used herein, refer to straight- or branched-chain hydrocarbon radicals containing from two to eight carbon atoms having at least one carbon-carbon triple bond by the removal of a single hydrogen atom. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butyne, heptynyl, octynyl, and the like.

The term "C₃-C₈-cycloalkyl", or "C₃-C₁₂-cycloalkyl," as used herein, refers to a monocyclic or polycyclic saturated carbocyclic ring compound. Examples of C₃-C₈-cycloalkyl include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl and cyclooctyl; and examples of C₃-C₁₂-cycloalkyl include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, and bicyclo [2.2.2] octyl.

The terms "C₂-C₈ alkylene," or "C₂-C₈ alkenylene," as used herein, refer to saturated or unsaturated respectively, straight- or branched-chain hydrocarbon diradicals containing between two and eight carbon atoms, while the diradical may reside at the same or different carbon atoms.

The term "C₃-C₈ cycloalkenyl", or "C₃-C₁₂ cycloalkenyl" as used herein, refers to monocyclic or polycyclic carbocyclic ring compound having at least one carbon-carbon double bond. Examples of C₃-C₈ cycloalkenyl include, but not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like; and examples of C₃-C₁₂ cycloalkenyl include, but not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like.

It is understood that any alkyl, alkenyl, alkynyl and cycloalkyl moiety described herein can also be an aliphatic group, an alicyclic group or a heterocyclic group. An "aliphatic" group is a non-aromatic moiety that may contain any combination of carbon atoms, hydrogen atoms, halogen atoms, oxygen, nitrogen or other atoms, and optionally contain one or more units of unsaturation, e.g., double and/or triple bonds. An aliphatic group may be straight chained, branched or cyclic and preferably contains between about 1 and about 24 carbon atoms, more typically

between about 1 and about 12 carbon atoms. In addition to aliphatic hydrocarbon groups, aliphatic groups include, for example, polyalkoxyalkyls, such as polyalkylene glycols, polyamines, and polyimines, for example. Such aliphatic groups may be further substituted.

5 The term “alicyclic,” as used herein, denotes a monovalent group derived from a monocyclic or bicyclic saturated carbocyclic ring compound by the removal of a single hydrogen atom. Examples include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, and bicyclo [2.2.2] octyl. Such alicyclic groups may be further substituted.

10 The terms “heterocyclic” or “heterocycloalkyl” can be used interchangeably and referred to a non-aromatic ring or a bi- or tri-cyclic group fused system, where (i) each ring system contains at least one heteroatom independently selected from oxygen, sulfur and nitrogen, (ii) each ring system can be saturated or unsaturated (iii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iv) the
15 nitrogen heteroatom may optionally be quaternized, (v) any of the above rings may be fused to an aromatic ring, and (vi) the remaining ring atoms are carbon atoms which may be optionally oxo-substituted. Representative heterocyclic groups include, but are not limited to, 1,3-dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl,
20 isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, and tetrahydrofuryl. Such heterocyclic groups may be further substituted.

 The term “substituted” refers to substitution by independent replacement of one, two, or three or more of the hydrogen atoms thereon with substituents
25 including, but not limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, -NO₂, -N₃, -CN, -NH₂, protected amino, oxo, thioxo, -NH-C₁-C₁₂-alkyl, -NH-C₂-C₈-alkenyl, -NH-C₂-C₈-alkynyl, -NH-C₃-C₁₂-cycloalkyl, -NH-aryl, -NH-heteroaryl, -NH-heterocycloalkyl, -dialkylamino, -diarylamino, -diheteroarylamino, -O-C₁-C₁₂-alkyl, -O-C₂-C₈-alkenyl, -O-C₂-C₈-alkynyl, -O-C₃-C₁₂-cycloalkyl, -O-aryl, -O-heteroaryl, -
30 O-heterocycloalkyl, -C(O)-C₁-C₁₂-alkyl, -C(O)-C₂-C₈-alkenyl, -C(O)-C₂-C₈-alkynyl, -C(O)-C₃-C₁₂-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH₂, -CONH-C₁-C₁₂-alkyl, -CONH-C₂-C₈-alkenyl, -CONH-C₂-C₈-alkynyl, -CONH-C₃-C₁₂-cycloalkyl, -CONH-aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl, -OCO₂-C₁-C₁₂-alkyl, -OCO₂-C₂-C₈-alkenyl, -OCO₂-C₂-C₈-

alkynyl, -OCO₂-C₃-C₁₂-cycloalkyl, -OCO₂-aryl, -OCO₂-heteroaryl, -OCO₂-heterocycloalkyl, -OCONH₂, -OCONH-C₁-C₁₂-alkyl, -OCONH-C₂-C₈-alkenyl, -OCONH-C₂-C₈-alkynyl, -OCONH-C₃-C₁₂-cycloalkyl, -OCONH-aryl, -OCONH-heteroaryl, -OCONH-heterocycloalkyl, -NHC(O)-C₁-C₁₂-alkyl, -NHC(O)-C₂-C₈-alkenyl, -NHC(O)-C₂-C₈-alkynyl, -NHC(O)-C₃-C₁₂-cycloalkyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO₂-C₁-C₁₂-alkyl, -NHCO₂-C₂-C₈-alkenyl, -NHCO₂-C₂-C₈-alkynyl, -NHCO₂-C₃-C₁₂-cycloalkyl, -NHCO₂-aryl, -NHCO₂-heteroaryl, -NHCO₂-heterocycloalkyl, -NHC(O)NH₂, -NHC(O)NH-C₁-C₁₂-alkyl, -NHC(O)NH-C₂-C₈-alkenyl, -NHC(O)NH-C₂-C₈-alkynyl, -NHC(O)NH-C₃-C₁₂-cycloalkyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, NHC(S)NH₂, -NHC(S)NH-C₁-C₁₂-alkyl, -NHC(S)NH-C₂-C₈-alkenyl, -NHC(S)NH-C₂-C₈-alkynyl, -NHC(S)NH-C₃-C₁₂-cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH₂, -NHC(NH)NH-C₁-C₁₂-alkyl, -NHC(NH)NH-C₂-C₈-alkenyl, -NHC(NH)NH-C₂-C₈-alkynyl, -NHC(NH)NH-C₃-C₁₂-cycloalkyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, -NHC(NH)-C₁-C₁₂-alkyl, -NHC(NH)-C₂-C₈-alkenyl, -NHC(NH)-C₂-C₈-alkynyl, -NHC(NH)-C₃-C₁₂-cycloalkyl, -NHC(NH)-aryl, -NHC(NH)-heteroaryl, -NHC(NH)-heterocycloalkyl, -C(NH)NH-C₁-C₁₂-alkyl, -C(NH)NH-C₂-C₈-alkenyl, -C(NH)NH-C₂-C₈-alkynyl, -C(NH)NH-C₃-C₁₂-cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C₁-C₁₂-alkyl, -S(O)-C₂-C₈-alkenyl, -S(O)-C₂-C₈-alkynyl, -S(O)-C₃-C₁₂-cycloalkyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)-heterocycloalkyl, -SO₂NH₂, -SO₂NH-C₁-C₁₂-alkyl, -SO₂NH-C₂-C₈-alkenyl, -SO₂NH-C₂-C₈-alkynyl, -SO₂NH-C₃-C₁₂-cycloalkyl, -SO₂NH-aryl, -SO₂NH-heteroaryl, -SO₂NH-heterocycloalkyl, -NHSO₂-C₁-C₁₂-alkyl, -NHSO₂-C₂-C₈-alkenyl, -NHSO₂-C₂-C₈-alkynyl, -NHSO₂-C₃-C₁₂-cycloalkyl, -NHSO₂-aryl, -NHSO₂-heteroaryl, -NHSO₂-heterocycloalkyl, -CH₂NH₂, -CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl, -C₃-C₁₂-cycloalkyl, polyalkoxyalkyl, polyalkoxy, -methoxymethoxy, -methoxyethoxy, -SH, -S-C₁-C₁₂-alkyl, -S-C₂-C₈-alkenyl, -S-C₂-C₈-alkynyl, -S-C₃-C₁₂-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl. It is understood that the aryls, heteroaryls, alkyls, and the like can be further substituted.

The term "halogen," as used herein, refers to an atom selected from fluorine, chlorine, bromine and iodine.

The term "hydroxy activating group", as used herein, refers to a labile chemical moiety which is known in the art to activate a hydroxyl group so that it will depart during synthetic procedures such as in a substitution or an elimination reaction. Examples of hydroxyl activating group include, but not limited to,

5 mesylate, tosylate, triflate, *p*-nitrobenzoate, phosphonate and the like.

The term "activated hydroxy", as used herein, refers to a hydroxy group activated with a hydroxyl activating group, as defined above, including mesylate, tosylate, triflate, *p*-nitrobenzoate, phosphonate groups, for example.

The term "hydroxy protecting group" or "thiol protecting group," as used

10 herein, refers to a labile chemical moiety which is known in the art to protect a hydroxyl group or thiol against undesired reactions during synthetic procedures. After said synthetic procedure(s) the hydroxy protecting group as described herein may be selectively removed. Hydroxy protecting groups as known in the art are described generally in T.H. Greene and P.G. M. Wuts, Protective Groups in Organic

15 Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of hydroxyl protecting groups include benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, isopropoxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-furfuryloxycarbonyl,

20 allyloxycarbonyl, acetyl, formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, *t*-butyl, 2,2,2-trichloroethyl, 2-trimethylsilyl ethyl, 1,1-dimethyl-2-propenyl, 3-methyl- 3 -butenyl, allyl, benzyl, para-methoxybenzyl, diphenylmethyl, triphenylmethyl (trityl), tetrahydrofuryl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl,

25 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, para-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, and the like. Preferred hydroxyl protecting groups for the present invention are acetyl (Ac or -C(O)CH₃), benzoyl (Bz or -C(O)C₆H₅), and trimethylsilyl (TMS or -Si(CH₃)₃).

The term "protected hydroxy," as used herein, refers to a hydroxy group

30 protected with a hydroxy protecting group, as defined above, including benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups, for example.

The term "hydroxy prodrug group", as used herein, refers to a promoietiy group which is known in the art to change the physicochemical, and hence the biological properties of a parent drug in a transient manner by covering or masking

the hydroxy group. After said synthetic procedure(s), the hydroxy prodrug group as described herein must be capable of reverting back to hydroxy group in vivo.

Hydroxy prodrug groups as known in the art are described generally in Kenneth B. Sloan, Prodrugs, Topical and Ocular Drug Delivery, (Drugs and the Pharmaceutical

5 Sciences; Volume 53), Marcel Dekker, Inc., New York (1992).

The term "amino protecting group," as used herein, refers to a labile chemical moiety which is known in the art to protect an amino group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the amino protecting group as described herein may be selectively removed. Amino

10 protecting groups as known in the art are described generally in T.H. Greene and P.G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of amino protecting groups include, but are not limited to, t-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, and the like.

15 The term "leaving group" means a functional group or atom which can be displaced by another functional group or atom in a substitution reaction, such as a nucleophilic substitution reaction. By way of example, representative leaving groups include chloro, bromo and iodo groups; sulfonic ester groups, such as mesylate, tosylate, brosylate, nosylate and the like; and acyloxy groups, such as acetoxo,

20 trifluoroacetoxo and the like.

The term "protected amino," as used herein, refers to an amino group protected with an amino protecting group as defined above.

The term "aprotic solvent," as used herein, refers to a solvent that is relatively inert to proton activity, i.e., not acting as a proton-donor. Examples

25 include, but are not limited to, hydrocarbons, such as hexane and toluene, for example, halogenated hydrocarbons, such as, for example, methylene chloride, ethylene chloride, chloroform, and the like, heterocyclic compounds, such as, for example, tetrahydrofuran and N-methylpyrrolidinone, and ethers such as diethyl ether, bis-methoxymethyl ether. Such compounds are well known to those skilled in

30 the art, and it will be obvious to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of aprotic solvents may be found in organic chemistry textbooks or in specialized monographs, for

example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick *et al.*, Vol. II, in the Techniques of Chemistry Series, John Wiley & Sons, NY, 1986.

5 The term “protic solvent” as used herein, refers to a solvent that tends to provide protons, such as an alcohol, for example, methanol, ethanol, propanol, isopropanol, butanol, t-butanol, and the like. Such solvents are well known to those skilled in the art, and it will be obvious to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of
10 protogenic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick *et al.*, Vol. II, in the Techniques of Chemistry Series, John Wiley & Sons, NY, 1986.

15 The term “hydrogen” includes deuterium and the listing of hydrogen and deuterium in the alternative with respect to some variables is not intended to infer or imply that other hydrogens are not intended to envision deuterium. In general, the identification of an element embraces the isotopes of the element, as suitable for the preparation a pharmaceutical.

20 Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term “stable”, as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or
25 prophylactic administration to a subject).

 The synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization. As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the Formula herein will be
30 evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock,

Comprehensive Organic Transformations, 2nd Ed. Wiley-VCH (1999); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.

The term "subject" as used herein refers to an animal. Preferably the animal is a mammal. More preferably the mammal is a human. A subject also refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, fish, birds and the like.

The compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and may include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

The compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optical isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art. Further details regarding resolutions can be found in Jacques, *et al.*, Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 1981). When the compounds described herein contain olefinic double bonds, other unsaturation, or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers or cis- and trans- isomers. Likewise, all tautomeric forms are also intended to be included. Tautomers may be in cyclic or acyclic. The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration unless the text so states; thus a carbon-carbon

double bond or carbon-heteroatom double bond depicted arbitrarily herein as *trans* may be *cis*, *trans*, or a mixture of the two in any proportion.

As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, *et al.* describes pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 66: 1-19 (1977). The salts can be prepared *in situ* during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Examples of pharmaceutically acceptable salts include, but are not limited to, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, *p*-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.

As used herein, the term "pharmaceutically acceptable ester" refers to esters which hydrolyze *in vivo* and include those that break down readily in the human

body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms.

- 5 Examples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.

The term "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of
10 humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present invention. "Prodrug", as used herein means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of the
15 invention. Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), *Design of Prodrugs*, Elsevier (1985); Widder, *et al.* (ed.), *Methods in Enzymology*, vol. 4, Academic Press (1985); Krogsgaard-Larsen, *et al.*, (ed). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991); Bundgaard, *et al.*, *Journal of Drug*
20 *Deliver Reviews*, 8:1-38(1992); Bundgaard, *J. of Pharmaceutical Sciences*, 77:285 et seq. (1988); Higuchi and Stella (eds.) *Prodrugs as Novel Drug Delivery Systems*, American Chemical Society (1975); Bernard Testa & Joachim Mayer, "Hydrolysis In Drug And Prodrug Metabolism: Chemistry, Biochemistry And Enzymology," John Wiley and Sons, Ltd. (2002); and J. Rautio *et al.*, "Prodrugs: design and clinical
25 applications", *Nature Review - Drug Discovery*, 7, 255-270 (2008).

The present invention also relates to solvates of the compounds of Formula (I), for example hydrates.

This invention also encompasses pharmaceutical compositions containing, and methods of treating viral infections through administering, pharmaceutically
30 acceptable prodrugs of compounds of the invention. For example, compounds of the invention having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or

carboxylic acid group of compounds of the invention. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters. Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in *J. Med. Chem.* 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.

PHARMACEUTICAL COMPOSITIONS

The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers or excipients.

As used herein, the term "pharmaceutically acceptable carrier or excipient" means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as

ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well
5 as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally,
10 vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the
15 formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

Liquid dosage forms for oral administration include pharmaceutically
20 acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene
25 glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

30 Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among

the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for

example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption
5 accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering
10 agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can
15 be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be
20 used include polymeric substances and waxes.

Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile
25 conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils,
30 waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium

silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.

Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving
5 or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

For pulmonary delivery, a therapeutic composition of the invention is
10 formulated and administered to the patient in solid or liquid particulate form by direct administration e.g., inhalation into the respiratory system. Solid or liquid particulate forms of the active compound prepared for practicing the present invention include particles of respirable size: that is, particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and
15 alveoli of the lungs. Delivery of aerosolized therapeutics, particularly aerosolized antibiotics, is known in the art (see, for example U.S. Pat. No. 5,767,068 to VanDevanter *et al.*, U.S. Pat. No. 5,508,269 to Smith *et al.*, and WO 98/43650 by Montgomery, all of which are incorporated herein by reference). A discussion of pulmonary delivery of antibiotics is also found in U.S. Pat. No. 6,014,969,
20 incorporated herein by reference.

According to the methods of treatment of the present invention, viral infections, conditions are treated or prevented in a patient such as a human or another animal by administering to the patient a therapeutically effective amount of a compound of the invention, in such amounts and for such time as is necessary to
25 achieve the desired result.

By a "therapeutically effective amount" of a compound of the invention is meant an amount of the compound which confers a therapeutic effect on the treated subject, at a reasonable benefit/risk ratio applicable to any medical treatment. The therapeutic effect may be objective (i.e., measurable by some test or marker) or
30 subjective (i.e., subject gives an indication of or feels an effect). A therapeutically effective amount of the compound described above may range from about 0.1 mg/Kg to about 500 mg/Kg, preferably from about 1 to about 50 mg/Kg. Effective doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents. It will be understood, however, that the total daily

usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or contemporaneously with the specific compound employed; and like factors well known in the medical arts.

The total daily dose of the compounds of this invention administered to a human or other animal in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. In general, treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of this invention per day in single or multiple doses.

The compounds of the invention described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.1 to about 500 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of a therapeutically effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with pharmaceutically excipients or carriers to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w).

Alternatively, such preparations may contain from about 20% to about 80% active compound.

Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.

Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

When the compositions of this invention comprise a combination of a compound of the invention described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.

The said "additional therapeutic or prophylactic agents" includes but not limited to, immune therapies (eg. interferon), therapeutic vaccines, antifibrotic agents, anti-inflammatory agents such as corticosteroids or NSAIDs, bronchodilators such as beta-2 adrenergic agonists and xanthines (e.g. theophylline), mucolytic agents, anti-muscarinics, anti-leukotrienes, inhibitors of cell adhesion (e.g. ICAM antagonists), anti-oxidants (eg N-acetylcysteine), cytokine agonists, cytokine antagonists, lung surfactants and/or antimicrobial and anti-viral agents (eg ribavirin and amantidine). The compositions according to the invention may also be used in combination with gene replacement therapy.

Unless otherwise defined, all technical and scientific terms used herein are accorded the meaning commonly known to one of ordinary skill in the art. All publications, patents, published patent applications, and other references mentioned herein are hereby incorporated by reference in their entirety.

5

PHARMACEUTICALLY ACCEPTABLE DERIVATIVES

The compound of the present invention can be administered as any derivative that upon administration to the recipient is capable of providing directly or indirectly, the parent compound. Further, the modifications can affect the biological activity of the compound, in some cases increasing the activity over the parent compound. This can easily be assessed by preparing the derivative and testing its antiviral and anti-proliferative activity according to the methods described herein, or other method known to those skilled in the art.

In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α -ketoglutarate and α -glycerophosphate. Suitable inorganic salts may also be formed, including sulfate, nitrate, bicarbonate, and carbonate salts.

Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.

Any of the nucleosides described herein can be administered as a nucleotide prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the nucleoside. A number of nucleotide prodrug ligands are known. In general, alkylation, acylation or other lipophilic modification of the mono, di or triphosphate of the nucleoside will increase the stability of the nucleotide. Examples of substituent groups that can replace one or more hydrogens on the phosphate moiety are alkyl, aryl, steroids, carbohydrates, including sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones and N. Bischofberger, *Antiviral*

Research, 27 (1995) 1-17. Any of these can be used in combination with the disclosed nucleosides to achieve a desired effect.

The nucleoside compound can also be provided as a 5'-phosphoether lipid or a 5'-ether lipid, as disclosed in the following references, which are incorporated by reference herein: Kucera, L. S. et al 1990. "Novel membrane interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation." *AIDS Res. Hum. Retro Viruses*. 6:491-501; Piantadosi, C., J. et al 1991. "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV activity." *J. Med. Chem.* 34:1408.1414; Hosteller, K. Y. et al 1992. "Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-deoxythymidine." *Antimicrob. Agents Chemother.* 36:2025.2029; Hosetler, K. Y., et al 1990. "Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides." *J. Biol. Chem.* 265:61127.

Nonlimiting examples of U.S. patents that disclose suitable lipophilic substituents that can be covalently incorporated into the nucleoside, preferably at the 5'-OH position of the nucleoside or lipophilic preparations, include U.S. Pat. Nos. 5,149,794 (Sep. 22, 1992, Yatvin et al.); 5,194,654 (Mar. 16, 1993, Hostetler et al., 5,223,263 (Jun. 29, 1993, Hostetler et al.); 5,256,641 (Oct. 26, 1993, Yatvin et al.); 5,411,947 (May 2, 1995, Hostetler et al.); 5,463,092 (Oct. 31, 1995, Hostetler et al.); 5,543,389 (Aug. 6, 1996, Yatvin et al.); 5,543,390 (Aug. 6, 1996, Yatvin et al.); 5,543,391 (Aug. 6, 1996, Yatvin et al.); and 5,554,728 (Sep. 10, 1996; Basava et al.), all of which are incorporated herein by reference. Foreign patent publications that disclose lipophilic substituents that can be attached to the nucleosides of the present invention, or lipophilic preparations, include WO 89/02733, WO 90/00555, WO 91/16920, WO 91/18914, WO 93/00910, WO 94/26273, WO 96/15132, EP 0 350 287, and WO 91/19721.

Nonlimiting examples of nucleotide prodrugs are described in the following references: J. K. Dickson, Jr. et al, "Orally active squalene synthetase inhibitors: bis((acyloxy)alkyl) prodrugs of the α -phosphonosulfonic acid moiety" *J. Med. Chem.* 1996, 39, 661-664; T. Kurz, et al, "Synthesis and antimalarial activity of chain substituted pivaloyloxymethyl ester analogues of Fosmidomycin and FR900098" *Bioorg. Med. Chem.* 2006, 14, 5121-5135; J. E. Starrett, Jr. et al,

- "Synthesis, oral bioavailability determination, and *in vitro* evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)" *J. Med. Chem.* 1994, 37, 1857-1864; H. T. Serafinowska, *et al*, "Synthesis and *in vivo* evaluation of prodrugs of 9-[2-(phosphonomethoxy)ethoxy]adenine" *J. Med. Chem.* 1995, 38, 1372-1379; S. Benzaria, *et al*, "Synthesis, *in vitro* antiviral evaluation, and stability studies of bis(*S*-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability" *J. Med. Chem.* 1996, 39, 4958-4965; M. S. Louie and H. Chapman, "An efficient process for the synthesis of cyclic HPMPC" *Nucleosides, Nucleotides Nucleic acid* 2001, 20, 1099-1102; J.-R. Choi, *et al*, "A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxy)-cyclopropyl)methyl]guanine as a potent and selective anti-HBV agent" *J. Med. Chem.* 2004, 47, 2864-2869; M. Wu, *et al*, "Synthesis of 9-[1-(substituted)-3-(phosphonomethoxy)propyl]adenine derivatives as possible antiviral agents" *Nucleosides, Nucleotides Nucleic acid.* 2005, 24, 1543-1568; X. Fu, *et al*, "Design and synthesis of novel bis(L-amino acid) ester prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) with improved anti-HBV activity" *Bioorg. Med. Chem. Lett.* 2007, 17, 465-470.

Similarly, the 5'-phosphonate can also be provided as various phosphonate prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the phosphonate. A number of phosphonate prodrug ligands are known. In general, alkylation, acylation or other lipophilic modification of one or more hydroxy on the phosphonate moiety can be used to achieve a desired effect.

COMBINATION AND ALTERNATION THERAPY FOR HIV, HBV OR HCV

It has been recognized that drug-resistant variants of HIV, HBV and HCV can emerge after prolonged treatment with an antiviral agent. Drug resistance most typically occurs by mutation of a gene that encodes for a protein such as an enzyme used in viral replication, and most typically in the case of HIV, reverse transcriptase, protease, or DNA polymerase, and in the case of HBV, DNA polymerase, or in the case of HCV, RNA polymerase, protease, or helicase. Recently, it has been demonstrated that the efficacy of a drug against HIV infection can be prolonged, augmented, or restored by administering the compound in combination or alternation with a second, and perhaps third, antiviral compound that induces a different

mutation from that caused by the principle drug. Alternatively, the pharmacokinetics, biodistribution, or other parameter of the drug can be altered by such combination or alternation therapy. In general, combination therapy is typically preferred over alternation therapy because it induces multiple simultaneous stresses on the virus.

The second antiviral agent for the treatment of HIV, in one embodiment, can be a reverse transcriptase inhibitor (a "RTI"), which can be either a synthetic nucleoside (a "NRTI") or a non-nucleoside compound (a "NNRTI"). In an alternative embodiment, in the case of HIV, the second (or third) antiviral agent can be a protease inhibitor. In other embodiments, the second (or third) compound can be a pyrophosphate analog, or a fusion binding inhibitor. A list compiling resistance data collected *in vitro* and *in vivo* for a number of antiviral compounds is found in Schinazi, et al, Mutations in retroviral genes associated with drug resistance, *International Antiviral News*, 1997.

Preferred compounds for combination or alternation therapy for the treatment of HBV include 3TC, FTC, L-FMAU, interferon, adefovir dipivoxil, entecavir, telbivudine (L-dT), valtorcitabine (3'-valinyl L-dC), β -D-dioxolanyl-guanine (DXG), β -D-dioxolanyl-2,6-diaminopurine (DAPD), and β -D-dioxolanyl-6-chloropurine (ACP), famciclovir, penciclovir, lobucavir, ganciclovir, and ribavirin.

Preferred examples of antiviral agents that can be used in combination or alternation with the compounds disclosed herein for HIV therapy include cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC); the (-)-enantiomer of 2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC); ziagen (abacavir), emtriva, viread (tenofovir DF), carbovir, acyclovir, foscarnet, interferon, AZT, DDI, D4T, CS-87 (3'-azido-2',3'-dideoxyuridine), and β -D-dioxolane nucleosides such as β -D-dioxolanyl-guanine (DXG), β -D-dioxolanyl-2,6-diaminopurine (DAPD), and β -D-dioxolanyl-6-chloropurine (ACP), and integrase inhibitors such as MK-0518.

Preferred protease inhibitors (PIs) include crixivan (indinavir), viracept (nelfinavir), norvir (ritonavir), invirase (saquinavir), aptivus (tipranavir), kaletra, lexiva (fosamprenavir), reyataz (atazanavir) and TMC-114.

Preferred Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) include rescripton (delavirdine), sustiva (efavirenz), viramune (nevirapine) and TMC-125.

Preferred Entry inhibitors include fuzeon (T-20), PRO-542, TNX-355, vicriviroc, aplaviroc and maraviroc.

A more comprehensive list of compounds that can be administered in combination or alternation with any of the disclosed nucleosides include (1S,4R)-4-[2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol succinate ("1592", a carbovir analog; GlaxoWellcome); 3TC: (-)- β -L-2',3'-dideoxy-3'-thiacytidine (GlaxoWellcome); a-APA R18893: a-nitro-anilino-phenylacetamide; A-77003; C2 symmetry-based protease inhibitor (Abbott); A-75925: C2 symmetry-based protease inhibitor (Abbott); AAP-BHAP: bishetero-aryl piperazine analog (Upjohn); ABT-538: C2-symmetry-based protease inhibitor (Abbott); AzddU: 3'-azido-2',3'-dideoxyuridine; AZT: 3'-azido-3'-deoxythymidine (GlaxoWellcome); AZT-p-ddI: 3'-azido-3'-deoxythymidyl-(5',5')-2',3'-dideoxyinosinic acid (Ivax); BHAP: bisheteroaryl-piperazine; BILA 1906: N-{1S-[[[3-[2S-{(1,1-dimethylethyl)amino]carbonyl}-4R]-3-pyridinylmethyl]thio]-1-piperidinyl]-2R-hydroxy-1S-(phenylmethyl)-propyl]amino]-carbonyl]-2-methylpropyl}-2-quinolinecarboxamide (Bio Mega/Boehringer-Ingelheim); BILA 2185: N-(1,1-dimethylethyl)-1-[2S-[[2-(2,6-dimethylphenoxy)-1-ethoxy]amino]-2R-hydroxy-4-phenylbutyl]-4R-pyridinylthio)-2-piperidinecarboxamide (BioMega/Boehringer-Ingelheim); BMS 186,318: aminodiol derivative HIV-1 protease inhibitor (Bristol-Myers-Squibb); d4API: 9-[2,5-d]hydro-5-(phosphonomethoxy)-2-furanyladenine (Gilead); d4C: 2',3'-didehydro-2',3'-dideoxycytidine; d4T: 2',3'-didehydro-3'-deoxythymidine (Bristol-Myers-Squibb); ddC: 2',3'-dideoxycytidine (Roche); ddI: 2',3'-dideoxyinosine (Bristol-Myers-Squibb); DMP-266: a 1,4-dihydro-2H-3,1-benzoxazin-2-one; DMP-450: {[4R-(4-a,5-a,6-b,7-b)]-hexahydro-5,6-bis(hydroxy)-1,3-bis(3-amino)phenyl]-methyl}-4,7-bis-(phenylmethyl)-2H-1,3-diazepin-2-one}-bismesylate (Gilead); DXG: (-)- β -D-dioxolane-guanosine (Gilead); EBU-dM: 5-ethyl-1-ethoxymethyl-6-(3,5-dimethylbenzyl)-uracil; E-EBU: 5-ethyl-1-ethoxymethyl-6-benzyluracil; DS: dextran sulfate; E-EPSeU: 1-(ethoxymethyl)-(6-phenylselenyl)-5-ethyluracil; E-EPU: 1-(ethoxymethyl)-(6-phenylthio)-5-ethyluracil; FTC: β -2',3'-dideoxy-5-fluoro-3'-thiacytidine (Gilead); HBY097: S-4-isopropoxycarbonyl-6-methoxy-3-(methylthio-methyl)-3,4-dihydroquinoxalin-2(1H)-thione; HEPT: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine; HIV-1: human immunodeficiency virus type 1; JM2763: 1,1'-(1,3-propanediyl)-bis-1,4,8,11-tetraaza-cyclotetradecane (Johnson Matthey); JM3100: 1,1'-[1,4-phenylenebis-

(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane (Johnson Matthey); KNI-272: (2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid-containing tripeptide; L-697,593: 5-ethyl-6-methyl-3-(2-phthalimido-ethyl)pyridin-2(1H)-one; L-735,524: hydroxy-amino-pentane amide HIV-1 protease inhibitor (Merck); L-697,661: 3-{[(4,7-dichloro-1,3-benzoxazol-2-yl)methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one; L-FDDC: (-)-β-L-5-fluoro-2',3'-dideoxycytidine; L-FDOC: (-)-β-L-5-fluoro-dioxolane cytosine; MKC442: 6-benzyl-1-ethoxymethyl-5-isopropyluracil (1-EBU; Mitsubishi); Nevirapine: 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyridol-[3,2-b:2',3'-e]-diazepin-6-one (Boehringer-Ingelheim); NSC648400: 1-benzyloxymethyl-5-ethyl-6-(alpha-pyridylthio)uracil (E-BPTU); P9941: [2-pyridylacetyl-IlePheAla-y(CHOH)]₂ (Dupont Merck); PFA: phosphonoformate (foscarnet; Astra); PMEa: 9-(2-phosphonylmethoxyethyl)adenine (Gilead); PMPA: (R)-9-(2-phosphonylmethoxypropyl)adenine (Gilead); Ro 31-8959: hydroxyethylamine derivative HIV-1 protease inhibitor (Roche); RPI-312: peptidyl protease inhibitor, 1-[(3S)-3-(n-alpha-benzyloxycarbonyl)-1-asparaginyl]-amino-2-hydroxy-4-phenylbutyryl]-n-tert-1-proline amide; 2720: 6-chloro-3,3-dimethyl-4-(isopropenyloxycarbonyl)-3,4-dihydro-quinoxalin-2-(1H)-thione; SC-52151: hydroxy-ethylurea isostere protease inhibitor (Searle); SC-55389A: hydroxyethyl-urea isostere protease inhibitor (Searle); TIBO R82150: (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk]-[1,4]benzodiazepin-2(1H)-thione (Janssen); TIBO 82913: (+)-(5s)-4, 5,6,7,-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,ljk]-[1,4]benzo-diazepin-2(1H)-thione (Janssen); TSAO-m3T: [2',5'-bis-O-(tert-butyl-dimethylsilyl)-3'-spiro-5'-(4'-amino-1',2'-oxathiole-2',2'-dioxide)]-β-D-pento-furanosyl-N3-methylthymine; U90152: 1-[3-[(1-methylethyl)-amino]-2-pyridinyl]-4-[[5-[(methylsulphonyl)-amino]-1H-indol-2-yl]carbonyl] piperazine; UC: thiocarboxanilide derivatives (Uniroyal); UC-781: N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-furancarbothioamide; UC-82: N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-thiophenecarbothioamide; VB 11,328: hydroxyethyl-sulphonamide protease inhibitor (Vertex); VX-478: hydroxyethylsulphonamide protease inhibitor (Vertex); XM 323: cyclic urea protease inhibitor (Dupont Merck).

The compound of the invention can also be administered in combination or alternation with ribavarin, interferon, interleukin or a stabilized prodrug of any of

them. More broadly described, the compound can be administered in combination or alternation with any of the anti-HCV drugs listed below.

Table of anti-Hepatitis C Compounds in Current Clinical Development		
Drug name	Drug category	Pharmaceutical Company
PEGASYS pegylated interferon alfa-2a	Long acting interferon	Roche
INFERGEN interferon alfacon-1	Long acting interferon	InterMune
OMNIFERON natural interferon	Long acting interferon	Viragen
ALBUFERON	Long acting interferon	Human Genome Sciences
REBIF interferon beta-1a	Interferon	Ares-Serono
Omega Interferon	Interferon	BioMedicine
Oral Interferon alpha	Oral Interferon	Amarillo Biosciences
Interferon gamma-lb	Anti-fibrotic	InterMune
IP-501	Anti-fibrotic	InterMune
Merimebodib VX-497	IMPDH inhibitor (inosine monophosphate dehydrogenase)	Vertex
AMANTADINE (Symmetrel)	Broad Antiviral Agent	Endo Labs Solvay
IDN-6556	Apoptosis regulation	Idun Pharma.
XTL-002	Monoclonal Antibody	XTL
HCV/MF59	Vaccine	Chiron
CIVACIR	Polyclonal Antibody Therapeutic vaccine	NABI Innogenetics
VIRAMIDINE	Nucleoside Analogue	ICN
ZADAXIN (thymosin alfa-1)	Immunomodulator	Sci Clone
CEPLENE (histamine)	Immunomodulator	Maxim
VX 950/LY 570310	Protease inhibitor	Vertex/Eli Lilly
ISIS 14803	Antisense	Isis Pharmaceutical/Elan
IDN-6556	Caspase inhibitor	Idun Pharmaceuticals
JTK 003	Polymerase Inhibitor	AKROS Pharma
Tarvacin	Anti-Phospholipid Therapy	Peregrine
HCV-796	Polymerase Inhibitor	ViroPharma/Wyeth
CH-6	Protease inhibitor	Schering
ANA971	Isatoribine	ANADYS
ANA245	Isatoribine	ANADYS
CPG 10101 (Actilon)	Immunomodulator	Coley
Rituximab (Rituxam)	Anti-CD20 Monoclonal Antibody	Genetech/IDEC
NM283 (Valopicitabine)	Polymerase Inhibitor	Idenix Pharmaceuticals
HepX TM -C	Monoclonal Antibody	XTL
IC41	Therapeutic Vaccine	Intercell
Medusa Interferon	Longer acting interferon	Flame1 Technologies
E-1	Therapeutic Vaccine	Innogenetics
Multiferon	Long Acting Interferon	Viragen
BILN 2061	Serine Protease inhibitor	Boehringer-Ingelheim
TMC435350	Serine Protease inhibitor	Tibotec
Boceprevir (SCH 503034)	Serine Protease inhibitor	Schering-Plough
nitazoxanide	To be determined	Romark
R7128/PSI6130	Polymerase Inhibitor	Roche/Pharmasset

IDX184	Polymerase Inhibitor	Idenix
R1626	Polymerase inhibitor	Roche
MK-7009	protease inhibitor	Merck
ITMN-191	protease inhibitor	InterMune
Debio 025	Cyclophilin inhibitor	Debiopharm

COMBINATION THERAPY FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS

In another embodiment, the compounds, when used as an antiproliferative, can be administered in combination with another compound that increases the effectiveness of the therapy, including but not limited to an antifolate, a 5-fluoropyrimidine (including 5-fluorouracil), a cytidine analogue such as β -L-1,3-dioxolanyl cytidine or β -L-1,3-dioxolanyl 5-fluorocytidine, antimetabolites (including purine antimetabolites, cytarabine, fudarabine, floxuridine, 6-mercaptapurine, methotrexate, and 6-thioguanine), hydroxyurea, mitotic inhibitors (including CPT-11, Etoposide (VP-21), taxol, and vinca alkaloids such as vincristine and vinblastine, an alkylating agent (including but not limited to busulfan, chlorambucil, cyclophosphamide, ifofamide, mechlorethamine, melphalan, and thiotepa), nonclassical alkylating agents, platinum containing compounds, bleomycin, an anti-tumor antibiotic, an anthracycline such as doxorubicin and dannomycin, an anthracenedione, topoisomerase II inhibitors, hormonal agents (including but not limited to corticosteroids (dexamethasone, prednisone, and methylprednisone), androgens such as fluoxymesterone and methyltestosterone, estrogens such as diethylstilbesterol, antiestrogens such as tamoxifen, LHRH analogues such as leuprolide, antiandrogens such as flutamide, aminoglutethimide, megestrol acetate, and medroxyprogesterone), asparaginase, carmustine, lomustine, hexamethyl-melamine, dacarbazine, mitotane, streptozocin, cisplatin, carboplatin, levamasole, and leucovorin. The compounds of the present invention can also be used in combination with enzyme therapy agents and immune system modulators such as an interferon, interleukin, tumor necrosis factor, macrophage colony-stimulating factor and colony stimulating factor.

Although the invention has been described with respect to various preferred embodiments, it is not intended to be limited thereto, but rather those skilled in the art will recognize that variations and modifications may be made therein which are within the spirit of the invention and the scope of the appended claims.

ABBREVIATIONS

Abbreviations which may be used in the descriptions of the scheme and the examples that follow are: Ac for acetyl; AcOH for acetic acid; AIBN for azobisisobutyronitrile; BINAP for 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl;

5 Boc₂O for di-*tert*-butyl-dicarbonate; Boc for *t*-butoxycarbonyl; Bpoc for 1-methyl-1-(4-biphenyl)ethyl carbonyl; Bz for benzoyl; Bn for benzyl; BocNHOH for *tert*-butyl N-hydroxycarbamate; *t*-BuOK for potassium *tert*-butoxide; Bu₃SnH for tributyltin hydride; BOP for (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium Hexafluorophosphate; Brine for sodium chloride solution in water; CDI for

10 carbonyldiimidazole; CH₂Cl₂ for dichloromethane; CH₃ for methyl; CH₃CN for acetonitrile; Cs₂CO₃ for cesium carbonate; CuCl for copper (I) chloride; CuI for copper (I) iodide; dba for dibenzylidene acetone; dppb for diphenylphosphino butane; DBU for 1,8-diazabicyclo[5.4.0]undec-7-ene; DCC for N,N'-dicyclohexylcarbodiimide; DEAD for diethylazodicarboxylate; DIAD for

15 diisopropyl azodicarboxylate; DIPEA or (i-Pr)₂EtN for N,N-diisopropylethyl amine; Dess-Martin periodinane for 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one; DMAP for 4-dimethylaminopyridine; DME for 1,2-dimethoxyethane; DMF for N,N-dimethylformamide; DMSO for dimethyl sulfoxide; DMT for di(*p*-methoxyphenyl)phenylmethyl or dimethoxytrityl; DPPA for diphenylphosphoryl

20 azide; EDC for N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide; EDC HCl for N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride; EtOAc for ethyl acetate; EtOH for ethanol; Et₂O for diethyl ether; HATU for O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium Hexafluorophosphate; HCl for hydrogen chloride; HOBt for 1-hydroxybenzotriazole; K₂CO₃ for potassium carbonate; *n*-

25 BuLi for *n*-butyl lithium; *i*-BuLi for *i*-butyl lithium; *t*-BuLi for *t*-butyl lithium; PhLi for phenyl lithium; LDA for lithium diisopropylamide; LiTMP for lithium 2,2,6,6-tetramethylpiperidinate; MeOH for methanol; Mg for magnesium; MOM for methoxymethyl; Ms for mesyl or -SO₂-CH₃; Ms₂O for methanesulfonic anhydride or mesyl-anhydride; NaN(TMS)₂ for sodium bis(trimethylsilyl)amide; NaCl for

30 sodium chloride; NaH for sodium hydride; NaHCO₃ for sodium bicarbonate or sodium hydrogen carbonate; Na₂CO₃ sodium carbonate; NaOH for sodium hydroxide; Na₂SO₄ for sodium sulfate; NaHSO₃ for sodium bisulfite or sodium hydrogen sulfite; Na₂S₂O₃ for sodium thiosulfate; NH₂NH₂ for hydrazine;

NH₄HCO₃ for ammonium bicarbonate; NH₄Cl for ammonium chloride; NMMO for N-methylmorpholine N-oxide; NaIO₄ for sodium periodate; Ni for nickel; OH for hydroxyl; OsO₄ for osmium tetroxide; TBAF for tetrabutylammonium fluoride; TEA or Et₃N for triethylamine; TFA for trifluoroacetic acid; THF for tetrahydrofuran; TMEDA for N,N,N',N'-tetramethylethylenediamine; TPP or PPh₃ for triphenyl-phosphine; Troc for 2,2,2-trichloroethyl carbonyl; Ts for tosyl or -SO₂-C₆H₄CH₃; Ts₂O for tolylsulfonic anhydride or tosyl-anhydride; TsOH for p-tolylsulfonic acid; Pd for palladium; Ph for phenyl; POPd for dihydrogen dichlorobis(di-tert-butylphosphinito-κP)palladate(II); Pd₂(dba)₃ for tris(dibenzylideneacetone) dipalladium (0); Pd(PPh₃)₄ for tetrakis(triphenylphosphine)palladium (0); PdCl₂(PPh₃)₂ for for trans-dichlorobis-(triphenylphosphine)palladium (II); Pt for platinum; Rh for rhodium; Ru for ruthenium; TBS for *tert*-butyl dimethylsilyl; TMS for trimethylsilyl; or TMSCl for trimethylsilyl chloride.

15

SYNTHETIC METHODS

The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes that illustrate the methods by which the compounds of the invention may be prepared. These schemes are of illustrative purpose, and are not meant to limit the scope of the invention. Equivalent, similar, or suitable solvents, reagents or reaction conditions may be substituted for those particular solvents, reagents, or reaction conditions described herein without departing from the general scope of the method of synthesis.

The syntheses of various nucleoside analogs have been well documented in the literature, the following reviews are incorporated hereinwith by references: D. M. Huryn and M. Okabe, *Chem. Rev.* 1992, 92, 1745; K. W. Pankiewicz, *Carbohydrate Research*, 2000, 327, 87-105; G. Gumina *et al*, *Antiviral Nucleosides: Chiral Synthesis and Chemotherapy*, C. K. Chu (Ed.), Elsevier, 2003, pages 1-76 and 77-189; nucleoside analogs used as antimetabolites have been summarized: M. M. Mader and J. R. Henry, *Comprehensive Medicinal Chemistry II*, Elsevier, 2007, Vol 7, pages 55-79; nucleoside analogs used as antiviral agents have been summarized: *Comprehensive Medicinal Chemistry II*, Elsevier, 2007, Vol 7, pages 295-327 by E. Littler and X-X Zhou; and pages 338-343 by T. A. Lyle; and pages


- 398-400 by U. Schmitz *et al.* The synthesis of each of these individual analog can be found in the literatures cited therein. Nonlimiting examples of process are also incorporated hereinwith by reference: Clark *et al*, *J. Med. Chem.* 2005, 48, 5504; Clark *et al*, *Bioorg. Med. Chem. Lett.* 2006, 16, 1712; Clark *et al*, *J. Carbohydr. Chem.* 2006, 25, 461; Seela *et al*, *Org. Biomol. Chem.* 2008, 6, 596; Pan *et al*, *J. Org. Chem.* 1999, 94, 4; Shi *et al*, *Bioorg. Med. Chem.* 2005, 13, 1641; He *et al*, *J. Org. Chem.* 2003, 68, 5519; Gudmundsson *et al*, *J. Med. Chem.* 2000, 43, 2473; Jean-Baptiste *et al*, *Synlett* 2008, 817; Wilson *et al*, *Synthesis* 1995, 1465; Lin *et al*, *J. Med. Chem.* 1991, 34, 2607; Matsuda *et al*, *J. Med. Chem.* 1991, 34, 812; Robins *et al*, *J. Med. Chem.* 1992, 35, 2283; Serafinowski *et al*, *Tetrahedron* 1996, 52, 7929; Serafinowski *et al*, *Tetrahedron* 2000, 56, 333; Houlton *et al*, *Tetrahedron* 1993, 49, 8087; Serafinowski *et al*, *Synthesis* 1997, 225; McCarthy *et al*, *Tetrahedron* 1996, 52, 45; Schmit, *Synlett* 1994, 241; Hirota *et al*, *ChemComm* 1999, 1827; Babu *et al*, *Org. Biomol. Chem.* 2003, 1, 3514; Samano *et al*, *J. Am. Chem. Soc.* 1992, 114, 4007; Beard *et al*, *Carbohydrate Res.* 1990, 87; Wigerinck *et al*, *J. Med. Chem.* 1991, 34, 2383; Ye *et al*, *J. Org. Chem.* 2005, 70, 7902; Eldrup *et al*, *J. Med. Chem.* 2004, 47, 2283 and 5284; Tang *et al*, *J. Org. Chem.* 1999, 64, 747; Jeannot *et al*, *Org. Biomol. Chem.* 2003, 1, 2096; Li *et al*, *Org. Lett.* 2001, 3, 1025; Marcotte *et al*, *Synthesis* 2001, 929; Dai *et al*, *Org. Lett.* 2001, 3, 807; Yoshimura *et al*, *Bioorg. Med. Chem. Lett.* 1994, 4, 721; Ohtawa *et al*, *J. Med. Chem.* 2007, 50, 2007; McGee *et al*, *J. Org. Chem.* 1996, 61, 781; Ogamino *et al*, *J. Org. Chem.* 2005, 70, 1684; Ichikawa *et al*, *Org. Biomol. Chem.* 2006, 4, 1284; Pan *et al*, *J. Org. Chem.* 1999, 64, 4; Huang *et al*, *J. Med. Chem.* 1991, 34, 1640; Kodama *et al*, *Tetrahedron* 2006, 62, 10011; He *et al*, *J. Org. Chem.* 2003, 68, 5519; Kumamoto *et al*, *J. Med. Chem.* 2006, 49, 7861; and Haraguchi *et al*, *Org. Lett.* 2004, 6, 2645.

- The synthesis of 4'-substituted nucleoside analogs have also been well documented in the literature, see references cited in a review article by Hayakawa *et al*, *Antiviral Chem. Chemother.* 2004, 15, 169 and nonlimiting examples of process: Cook *et al*, *J. Am. Chem. Soc.* 1979, 101, 1554; Haraguchi *et al*, *J. Med. Chem.* 2008, 51, 1885; Kubota *et al*, *J. Org. Chem.* 2006, 71, 1099; Haraguchi *et al*, *Org. Lett.* 2003, 5, 1399; Haraguchi *et al*, *J. Org. Chem.* 2006, 71, 4433; Haraguchi *et al*, *J. Am. Chem. Soc.* 1975, 97, 4433; Maag *et al*, *J. Med. Chem.* 1992, 35, 1440; Marx *et al*, *Helv. Chim. Acta* 1996, 79, 1980; Youssefyeh *et al*, *J. Org. Chem.* 1979, 44,


1301; Jones *et al*, *J. Org. Chem.* 1979, 44, 1309; Perrone *et al*, *J. Med. Chem.* 2007, 50, 5463; Smith *et al*, *Bioorg. Med. Chem. Lett.* 2007, 17, 2570; Nomura *et al*, *J. Med. Chem.* 1999, 42, 2901; and Maag *et al*, *J. Med. Chem.* 1994, 37, 431.

One of the general procedures to synthesize the 4'-allenic nucleosides (**Ia**) of the present invention is shown in Scheme 1, in which 4'-substituents containing a alkyne moiety can be transformed and/or isomerized to a allenic moiety under a variety of conditions, for example heat, base, or a metal or combination of metals as catalyst or promoter, optionally in the presence of an additive such as Lewis acid, metal salt, phase-transfer-catalyst and/or nucleophile, wherein hereinafter unless otherwise defined, R₁, R₂, R_{2a}, R₃, R_{3a}, R_{4a}, R_{4b}, R_{4c}, B and X are as previously defined; PG is a hydroxy protecting group; and LG is a leaving group such as halide, OH, OAc, OBoc, OMs, OTf or the like. For example the conversion from alkynes (**1-1**) or (**1-1a**) to (**Ia**) can be realized in the presence of a base such as alkyl lithium (MeLi or n-BuLi or the like), LDA, NaH, t-BuOK, KOH, Cs₂CO₃ or the like, in an aprotic solvent such as THF, DMF, or the like at temperature from -78°C to 150°C, optionally in the presence of a nucleophile of formula R_{4b}-M-LG or R_{4a}-M-LG wherein M is a metal such as Mg and LG is as previously defined; after removal of the protecting group. The conversion from alkynes (**1-2**) or (**1-2a**) to (**Ia**) can be realized in the presence of a transition metal compound or metal ion or combination of two or more thereof, such as CuI, CuCN, Pd(PPh)₄-CuI, Pd₂(dba)₃, or the like, in an aprotic solvent such as THF, DMF, DMSO or the like at temperature from -78°C to 150°C; optionally in the presence of a salt such as LiBr, ammonium formate or the like, or a nucleophile of formula R_{4b}-M-LG or R_{4a}-M-LG wherein M and LG are as previously defined; after removal of the protecting group.

25



Another general procedure to synthesize the 4'-allenic nucleosides (**Ia-1**) of the present invention is shown in Scheme 2, wherein PG stands for a hydroxy protecting group. The starting ketals (**2-1**) are known in the art, see the nonlimiting examples of process cited above in this section. It was treated with an acid (such as MeSO₃H or TsOH or the like) or a Lewis acid (such as BF₃, SnCl₄, FeCl₃, InCl₃, TMSOTf or the like) in the presence of an alkyne such as propargyl trimethylsilane to give the 4'-allene (**Ia-1**) in an aprotic solvent such as MeCN, CH₂Cl₂ or the like at a temperature from -78°C to refluxing temperature depending on the choice of solvent.



15

The synthesis of nucleoside 5'-monophosphate prodrugs have also been well documented in the literature, see references cited in accounts by Cahard *et al*, *Mini-Reviews Med. Chem.* 2004, 4, 371; Meier *et al*, *Mini-Reviews Med. Chem.* 2004, 4, 383; Peyrottes *et al*, *Mini-Reviews Med. Chem.* 2004, 4, 395; Drontle *et al*, *Mini-Reviews Med. Chem.* 2004, 4, 409; and nonlimiting examples of recent process:

20

Gisch *et al*, *J. Med. Chem.* 2007, 50, 1658; Boyer *et al*, *J. Med. Chem.* 2006, 49, 7711; Khamnei *et al*, *J. Med. Chem.* 1996, 39, 4109; Li *et al*, *Synlett* 2004, 2600; Perrone *et al*, *J. Med. Chem.* 2007, 50, 5463; Gisch *et al*, *J. Med. Chem.* 2007, 50, 1658 and 1840; Hecker *et al*, *J. Med. Chem.* 2007, 50, 3891; Prakash *et al*, *J. Med.*
5 *Chem.* 2005, 48, 1199; and Gunic *et al*, *Bioorg. Med. Chem. Lett.* 2007, 17, 2452 (for 3',5'-cyclic monophosphate prodrug).

The synthesis of nucleoside phosphonates and/or their prodrugs have also been well documented in the literature, see references cited in accounts by Hecker *et al*, *J. Med. Chem.* 2008, 51, 2328; Krise *et al*, *Adv. Drug Deliv. Rev.* 1996, 19, 287;
10 Berkowitz *et al*, *J. Fluorine Chem.* 2001, 112, 13; Romanenko *et al*, *Chem. Rev.* 2006, 106, 3868; De Clercq, *Antiviral Res.* 2007, 75, 1; De Clercq *et al*, *Nat. Rev.- Drug Disc.* 2005, 4, 928; and nonlimiting examples of recent process: Mackman *et al*, *Bioorg. Med. Chem.* 2007, 15, 5519; Dang *et al*, *Bioorg. Med. Chem. Lett.* 2007, 17, 3412; Meier *et al*, *J. Med. Chem.* 2005, 48, 8079; Wu *et al*,
15 *Nucleosides Nucleotides Nucl. Acids* 2005, 24, 1543; Choi *et al*, *J. Med. Chem.* 2004, 47, 2864; Sekiya *et al*, *J. Med. Chem.* 2002, 45, 3138; Louie *et al*, *Nucleosides Nucleotides Nucl. Acids* 2001, 20, 1099; Serafinowska *et al*, *J. Med. Chem.* 1995, 38, 1372; Koh *et al*, *J. Med. Chem.* 2005, 48, 2867; Mackman *et al*, *Bioorg. Med. Chem.* 2007, 15, 5519; Wang *et al*, *Nucleosides Nucleotides Nucl. Acids* 2004, 23, 317; Dyatkina *et al*, *Tetrahedron* 1995, 51, 761; Reddy *et al*, *J. Med. Chem.* 2008, 51, 666; Krecmerova *et al*, *J. Med. Chem.* 2007, 50, 5765.
20

It will be appreciated that, with appropriate manipulation and protection of any chemical functionality, synthesis of compounds of Formula (I) is accomplished by methods analogous to those above and to those described in the Experimental
25 section. Suitable protecting groups can be found, but are not restricted to, those found in T W Greene and P G M Wuts "Protective Groups in Organic Synthesis", 3rd Ed (1999), J Wiley and Sons.

All references cited herein, whether in print, electronic, computer readable storage media or other form, are expressly incorporated by reference in their
30 entirety, including but not limited to, abstracts, articles, journals, publications, texts, treatises, internet web sites, databases, patents, and patent publications.

EXAMPLES

The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration only and not limiting of the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the chemical structures, substituents, derivatives, formulations and/or methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims.

Although the invention has been described with respect to various preferred embodiments, it is not intended to be limited thereto, but rather those skilled in the art will recognize that variations and modifications may be made therein which are within the spirit of the invention and the scope of the appended claims.

Example 1. Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_{2a} = R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = 3\text{-methoxycarbonyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl}$.

Step 1a. Into a solution of trimethylsilyl acetylene (0.53 mL, 3.72 mmol) in anhydrous THF (6 mL) at 0 °C was added ethylmagnesium bromide (1 M in THF, 3.0 mL, 2.98 mmol). The mixture was gradually warmed up to ambient temperature for 20 min before being cooled back to 0 °C. A solution of 1-[2,3,5-Tris-*O*-(*tert*-butyldimethyl-silyl)-4 α -formyl- β -D-ribo-pentofuranosyl]uracil (prepared according to the process by M. Nomura *et al*, *J. Med. Chem.* **1999**, 42, 2901; 0.457 g, 0.744 mmol) in THF (8 mL) was then added and the resulting mixture was stirred at this temperature for 1 h before charging methyl chloroformate (0.34 mL, 4.47 mmol). The mixture was then slowly warmed up to ambient temperature and stirred overnight before being quenched with aqueous NaHCO₃ and partitioned (ethyl acetate - water). The organics were washed with brine, dried over (Na₂SO₄) and evaporated. The residue was chromatographed (silica, hexanes-EtOAc) to give the desired compound (0.579 g, 94%) as a colorless oil. ESIMS $m/z = 829.35 [M+H]^+$.

Step 1b. A mixture of the compound from step 1a (0.579 g, 0.699 mmol) and silver nitrate (0.474 g, 2.79 mmol) in ethanol (36 mL) and water (9 mL) was stirred at ambient temperature for 3 h before charging potassium iodide (0.696 g, 4.19 mmol). It was stirred for 15 min before passing through a short pad of silica gel. The filtrate

was partitioned (ethyl acetate - water) and the organics were washed with brine, dried (Na₂SO₄) and evaporated. The residue was chromatographed (silica, hexanes-EtOAc) to give the desired compound (0.470 g, 89%) as a white foam. ESIMS m/z = 757.33 [M+H]⁺.

- 5 **Step 1c.** A mixture of tris(dibenzylideneacetone)dipalladium(0) (56.8 mg, 62.1 μ mol), ammonium formate (0.117 g, 1.87 mmol) and tri-*n*-butyl phosphine (64.5 μ L, 0.249 mmol) in anhydrous DMF (14 mL) was degassed and stirred at ambient temperature for 20 min under N₂. A solution of the compound from step 1b (0.470 g, 0.621 mmol) in DMF (9 mL) was added and the mixture was slowly heated up to 70
10 °C and kept there for 30 min before cooling to ambient temperature and diluting with ethyl acetate. The greenish mixture was partitioned (ethyl acetate - water) and the organics were washed with brine, dried (Na₂SO₄) and evaporated. The residue was chromatographed (silica, hexanes-EtOAc) to give the title compound (0.252 g, 59%) as a colorless oil. ESIMS m/z = 683.40 [M+H]⁺. ¹H NMR (CDCl₃): 8.05 (d, J = 8.5 Hz, 1H), 5.85 (d, J = 3.5 Hz, 1H), 5.66 (d, J = 8.5 Hz, 1H), 5.49 (t, J = 7.0 Hz, 1H), 4.83 (dd, J = 6.5, 11.0 Hz, 1H), 4.78 (dd, J = 6.5, 11.0 Hz, 1H), 4.14 (d, J = 5.0 Hz, 1H), 4.10 (dd, J = 3.0, 5.0 Hz, 1H), 3.98 (s, 3H), 3.76 (d, J = 11.5 Hz, 1H), 3.65 (d, J = 11.5 Hz, 1H), 0.85 (m, 27H), 0.06 (m, 18H).

- 20 **Example 2.** Compound of Formula (I), wherein R₁ = R₂ = R₃ = R_{4a} = R_{4b} = R_{4c} = H, R_{2a} = R_{3a} = R₅ = OTBS, X = O, L = CH₂, B = uracil-1-yl.

- The compound of example 1 (0.252 g, 0.369 mmol) was treated with ammonia (7 N in methanol, 25 mL) at ambient temperature overnight before being evaporated. The residue was chromatographed (silica, hexanes-EtOAc) to give the title compound
25 (0.201 g, 87%) as a light yellow oil. ESIMS m/z = 625.33 [M+H]⁺. ¹H NMR (CDCl₃): 9.16 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 5.83 (d, J = 3.0 Hz, 1H), 5.60 (d, J = 8.0 Hz, 1H), 5.50 (t, J = 7.0 Hz, 1H), 4.81 (dd, J = 6.5, 11.0 Hz, 1H), 4.75 (dd, J = 6.5, 11.0 Hz, 1H), 4.15 (d, J = 5.0 Hz, 1H), 4.07 (dd, J = 3.0, 5.0 Hz, 1H), 3.74 (d, J = 12.0 Hz, 1H), 3.62 (d, J = 11.5 Hz, 1H), 0.83 (m, 27H), 0.03 (m, 18H).

30

Example 3. Compound of Formula (I), wherein R₁ = R₂ = R₃ = R_{4a} = R_{4b} = R_{4c} = H, R_{2a} = R_{3a} = R₅ = OTBS, X = O, L = CH₂, B = cytosine-1-yl.

Into a solution of the compound of example 2 (50.0 mg, 80.1 μ mol) in anhydrous MeCN (6 mL) were added triethylamine (46.0 μ L, 0.320 mmol), DMAP (4.9 mg,

40.0 μmol) and 2,4,6-triisopropylbenzenesulfonyl chloride (36.3 mg, 0.120 mmol) sequentially. It was stirred at ambient temperature for 1 h before charging aqueous ammonium hydroxide (28%-30%, 8 mL). The mixture was stirred overnight before being evaporated. The residue was chromatographed (silica, CH_2Cl_2 -MeOH) to give the title compound (29.3 mg, 60%) as a light yellow oil. ESIMS m/z = 624.37 [M+H]⁺. ¹H NMR (CD_3OD): 8.00 (d, J = 7.5 Hz, 1H), 5.90 (d, J = 3.0 Hz, 1H), 5.80 (d, J = 7.0 Hz, 1H), 5.51 (t, J = 7.0 Hz, 1H), 4.82 (dd, J = 6.5, 11.0 Hz, 1H), 4.76 (dd, J = 6.5, 11.0 Hz, 1H), 4.25 (d, J = 5.0 Hz, 1H), 4.16 (dd, J = 3.5, 5.0 Hz, 1H), 3.77 (d, J = 11.0 Hz, 1H), 3.71 (d, J = 12.0 Hz, 1H), 0.88 (m, 27H), 0.06 (m, 18H).

Example 4. Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = \text{H}$, $R_{2a} = R_{3a} = R_5 = \text{OH}$, $X = \text{O}$, $L = \text{CH}_2$, $B = \text{cytosine-1-yl}$.

A solution of the compound of example 3 (29.3 mg, 47.0 μmol) in anhydrous THF (9 mL) was treated with TBAF (1M in THF, 0.16 mL, 0.164 mmol) at room temperature overnight before being evaporated. The residue was chromatographed (silica, CH_2Cl_2 -MeOH) to give the title compound (1.5 mg) as a white foam. ESIMS m/z = 282.17 [M+H]⁺. ¹H NMR (CD_3OD): 8.06 (d, J = 7.0 Hz, 1H), 5.95 (d, J = 4.5 Hz, 1H), 5.90 (d, J = 7.0 Hz, 1H), 5.49 (t, J = 7.0 Hz, 1H), 4.90 (m, 2H), 4.31 (d, J = 6.0 Hz, 1H), 4.27 (dd, J = 4.5, 6.0 Hz, 1H), 3.71 (s, 2H).

Example 5. Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = \text{H}$, $R_{2a} = R_{3a} = R_5 = \text{OH}$, $X = \text{O}$, $L = \text{CH}_2$, $B = \text{uracil-1-yl}$.

A solution of the compound of example 2 (0.270 g, 0.432 mmol) in anhydrous THF (20 mL) was treated with TBAF (1M in THF, 1.34 mL, 1.34 mmol) at room temperature overnight before being evaporated. The residue was chromatographed (silica, CH_2Cl_2 -MeOH) to give the title compound (59.6 mg, 49%) as a white solid. ESIMS m/z = 283.14 [M+H]⁺. ¹H NMR (CD_3OD): 8.04 (d, J = 8.5 Hz, 1H), 5.99 (d, J = 5.5 Hz, 1H), 5.73 (d, J = 7.5 Hz, 1H), 5.47 (t, J = 6.5 Hz, 1H), 4.89 (m, 2H), 4.33 (m, 1H), 4.28 (d, J = 5.5 Hz, 1H), 3.70 (s, 2H).

Example 6. Compound of Formula (Ib), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = \text{H}$, $R_{2a} = R_{3a} = \text{OH}$, $R_5 = -\text{OP}(\text{O})(\text{OPh})(\text{NHCHMeCO}_2\text{Me})$, $X = \text{O}$, $L = \text{CH}_2$, $B = \text{uracil-1-yl}$.

A solution of the compound of example 5 (57.0 mg, 0.202 mmol) in anhydrous THF (6 mL) was treated with *tert*-butylmagnesium chloride (1M in THF, 0.40 mL, 0.404 mmol) at room temperature for 15 min before charging phenyl-(methoxy-L-alaninyl)-phosphorochloridate (0.140 g, 0.505 mmol). Stirring was continued at room temperature overnight before being quenched with aqueous NH₄Cl. The mixture was partitioned (ethyl acetate - water) and the organics were washed with brine, dried (Na₂SO₄) and evaporated. The residue was chromatographed (silica, CH₂Cl₂-MeOH) to give the title compound (6.8 mg, 6%) as a colorless oil. ESIMS $m/z = 524.14$ [M+H]⁺.

10

Example 7. Compound of Formula (I), wherein R₁ = R_{2a} = R₃ = R_{4a} = R_{4b} = R_{4c} = H, R₂ = F, R_{3a} = R₅ = OTBS, X = O, L = CH₂, B = 3-methoxycarbonyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl.

Step 7a. Into a solution of trimethylsilyl acetylene (1.07 mL, 7.59 mmol) in anhydrous THF (10 mL) at 0 °C was added ethylmagnesium bromide (1 M in THF, 6.5 mL, 6.50 mmol). The mixture was gradually warmed up to ambient temperature for 20 min before being cooled back to 0 °C. A solution of 3-(*tert*-Butyl-dimethyl-silanyloxy)-2-(*tert*-butyl-dimethyl-silanyloxymethyl)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-tetrahydro-furan-2-carbaldehyde (prepared from commercial available 1-(3-Fluoro-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione according to the process by M. Nomura *et al*, *J. Med. Chem.* **1999**, 42, 2901; 0.544 g, 1.08 mmol) in THF (10 mL) was then added and the resulting mixture was stirred at this temperature for 1 h before charging methyl chloroformate (0.67 mL, 8.67 mmol). The mixture was then slowly warmed up to ambient temperature and stirred overnight before being quenched with aqueous NaHCO₃ and partitioned (ethyl acetate - water). The organics were washed with brine, dried over (Na₂SO₄) and evaporated. The residue was chromatographed (silica, hexanes-EtOAc) to give the desired compound (0.582 g, 75%) as white foam. ESIMS $m/z = 717.51$ [M+H]⁺.

Step 7b. A mixture of the compound from step 7a (0.582 g, 0.812 mmol) and silver nitrate (0.276 g, 1.63 mmol) in ethanol (36 mL) and water (9 mL) was stirred at ambient temperature for 3 h before charging potassium iodide (0.405 g, 2.44 mmol). It was stirred for 15 min before passing through a short pad of silica gel. The filtrate was partitioned (ethyl acetate - water) and the organics were washed with brine,

dried (Na_2SO_4) and evaporated. The residue was chromatographed (silica, hexanes-EtOAc) to give the desired compound (0.500 g, 98%) as a colorless oil. ESIMS $m/z = 645.50$ $[\text{M}+\text{H}]^+$.

Step 7c. A mixture of tris(dibenzylideneacetone)dipalladium(0) (71.1 mg, 77.6 μmol), ammonium formate (0.147 g, 2.33 mmol) and tri-*n*-butyl phosphine (80.6 μL , 0.311 mmol) in anhydrous DMF (18 mL) was degassed and stirred at ambient temperature for 20 min under N_2 . A solution of the compound from step 7b (0.500 g, 0.776 mmol) in DMF (12 mL) was added and the mixture was slowly heated up to 70 °C and kept there for 30 min before cooling to ambient temperature and diluting with ethyl acetate. The greenish mixture was partitioned (ethyl acetate - water) and the organics were washed with brine, dried (Na_2SO_4) and evaporated. The residue was chromatographed (silica, hexanes-EtOAc) to give the title compound (0.120 g, 27%) as a colorless oil. ESIMS $m/z = 571.47$ $[\text{M}+\text{H}]^+$.

Example 8. Compound of Formula (I), wherein $\text{R}_1 = \text{R}_{2a} = \text{R}_3 = \text{R}_{4a} = \text{R}_{4b} = \text{R}_{4c} = \text{H}$, $\text{R}_2 = \text{F}$, $\text{R}_{3a} = \text{R}_5 = \text{OTBS}$, $\text{X} = \text{O}$, $\text{L} = \text{CH}_2$, $\text{B} = \text{uracil-1-yl}$.

The compound of example 7 (0.120 g, 0.210 mmol) was treated with ammonia (7 N in methanol, 25 mL) at ambient temperature overnight before being evaporated. The residue was chromatographed (silica, hexanes-EtOAc) to give the title compound (66.0 mg, 62%) as a light yellow oil. ESIMS $m/z = 513.40$ $[\text{M}+\text{H}]^+$.

Example 9. Compound of Formula (I), wherein $\text{R}_1 = \text{R}_{2a} = \text{R}_3 = \text{R}_{4a} = \text{R}_{4b} = \text{R}_{4c} = \text{H}$, $\text{R}_2 = \text{F}$, $\text{R}_{3a} = \text{R}_5 = \text{OTBS}$, $\text{X} = \text{O}$, $\text{L} = \text{CH}_2$, $\text{B} = \text{cytosine-1-yl}$.

Into a solution of the compound of example 8 (0.130 g, 0.254 mmol) in anhydrous MeCN (8 mL) were added triethylamine (0.14 mL, 1.02 mmol), DMAP (15.5 mg, 0.127 mmol) and 2,4,6-triisopropylbenzenesulfonyl chloride (0.115 g, 0.381 mmol) sequentially. It was stirred at ambient temperature for 1 h before charging aqueous ammonium hydroxide (28%-30%, 11 mL). The mixture was stirred overnight before being evaporated. The residue was chromatographed (silica, CH_2Cl_2 -MeOH) to give the title compound (0.105 g, 81%) as a white solid. ESIMS $m/z = 512.47$ $[\text{M}+\text{H}]^+$.

Example 10. Compound of Formula (I), wherein $\text{R}_1 = \text{R}_{2a} = \text{R}_3 = \text{R}_{4a} = \text{R}_{4b} = \text{R}_{4c} = \text{H}$, $\text{R}_2 = \text{F}$, $\text{R}_{3a} = \text{R}_5 = \text{OH}$, $\text{X} = \text{O}$, $\text{L} = \text{CH}_2$, $\text{B} = \text{cytosine-1-yl}$.

A solution of the compound of example 9 (0.105 g, 0.205 mmol) in anhydrous THF (6 mL) was treated with TBAF (1M in THF, 0.45 mL, 0.451 mmol) at room temperature overnight before being evaporated. The residue was chromatographed (silica, CH₂Cl₂-MeOH) to give the title compound (13.9 mg, 24%) as a white foam.

5 ESIMS m/z = 284.20 [M+H]⁺.

Example 11. Compound of Formula (I), wherein R₁ = R₃ = R_{4a} = R_{4b} = R_{4c} = H, R₂ = R_{2a} = F, R_{3a} = R₅ = OTBS, X = O, L = CH₂, B = 3-methoxycarbonyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl.

10 **Step 11a.** Into a solution of trimethylsilyl acetylene (0.68 mL, 4.81 mmol) in anhydrous THF (7 mL) at 0 °C was added ethylmagnesium bromide (1.0 M in THF, 3.85 mL, 3.85 mmol). The mixture was stirred at 0 °C for 10 min, then at room temperature for 10 min before being cooled back to 0 °C. A solution of 1-[2,2-difluoro-3,5-bis-*O*-(*tert*-butyldimethylsilyl)-4 α -formyl- β -D-ribo-

15 pentofuranosyl]uracil (prepared from commercial available 2'-deoxy-2',2'-difluoro-D-uridine according to the process by M. Nomura *et al*, *J. Med. Chem.* **1999**, 42, 2901; 0.501 g, 0.962 mmol) in THF (9 mL) was then added and the resulting mixture was stirred at 0 °C for 1.5 h before treated with methyl chloroformate (0.45 mL, 5.77 mmol) at 0 °C. The mixture was then allowed to slowly warm up to room

20 temperature and stirred overnight before being quenched with aqueous NaHCO₃ and partitioned (ethyl acetate - water). The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over (Na₂SO₄) and evaporated. The residue was chromatographed (silica, dichloromethane) to give the desired compound (0.681 g, 96%) as a colorless oil. ESIMS m/z = 735.55

25 [M+H]⁺.

Step 11b. A mixture of the compound from step 11a (0.681 g, 0.926 mmol) and silver nitrate (0.315 g, 1.853 mmol) in ethanol (36 mL) and water (9 mL) was stirred at room temperature for 30 min. Potassium iodide (0.461 g, 2.780 mmol) was added in one portion. The suspension was stirred at room temperature for 15 min before

30 being filtered through a short pad of silica gel, washing with ethyl acetate. The filtrate was concentrated. The residue was chromatographed (silica, dichloromethane) to give the desired compound (0.530 g, 86%) as a white foam. ESIMS m/z = 663.49 [M+H]⁺.

Step 11c. A mixture of tris(dibenzylideneacetone)dipalladium(0) (71.0 mg, 77.5 μmol), ammonium formate (0.147 g, 2.326 mmol) and tri-*n*-butyl phosphine (79.0 μL , 0.310 mmol) in anhydrous DMF (18 mL) was degassed and stirred at room temperature for 20 min under N_2 . A solution of the compound from step 11b (0.514 g, 0.775 mmol) in DMF (12 mL) was added and the mixture was slowly heated up to 70 °C and kept at 70 °C for 20 min before being allowed to cool down to room temperature and diluted with ethyl acetate and H_2O . The organic layer was washed with brine (*2), dried (Na_2SO_4) and evaporated. The residue was chromatographed (silica, hexanes-EtOAc) to give product of Example 2 (0.133 g, contains some starting material) as a colorless oil and the title compound (0.102 g, contains some Bu_3P) as a colorless oil. ESIMS $m/z = 589.50 [\text{M}+\text{H}]^+$.

Example 12. Compound of Formula (I), wherein $\text{R}_1 = \text{R}_3 = \text{R}_{4a} = \text{R}_{4b} = \text{R}_{4c} = \text{H}$, $\text{R}_2 = \text{R}_{2a} = \text{F}$, $\text{R}_{3a} = \text{R}_5 = \text{OTBS}$, $\text{X} = \text{O}$, $\text{L} = \text{CH}_2$, $\text{B} = \text{uracil-1-yl}$.

The compound of example 11 (0.102 g, maximum 0.173 mmol) was treated with ammonia (7 N in methanol, 15 mL) at room temperature overnight before being evaporated. The residue was combined with impure product from example 11 (0.133 g, contains some starting material of step 11c) and was chromatographed (silica, hexanes-EtOAc) to give the title compound (0.116 g, 28% over 2 steps) as a colorless oil. ESIMS $m/z = 531.47 [\text{M}+\text{H}]^+$.

Example 13. Compound of Formula (I), wherein $\text{R}_1 = \text{R}_3 = \text{R}_{4a} = \text{R}_{4b} = \text{R}_{4c} = \text{H}$, $\text{R}_2 = \text{R}_{2a} = \text{F}$, $\text{R}_{3a} = \text{R}_5 = \text{OTBS}$, $\text{X} = \text{O}$, $\text{L} = \text{CH}_2$, $\text{B} = \text{cytosine-1-yl}$.

Into a solution of the compound of example 12 (0.116 g, 0.219 mmol) in anhydrous MeCN (8 mL) were added triethylamine (0.12 mL, 0.875 mmol), DMAP (13.4 mg, 0.109 mmol) and 2,4,6-triisopropylbenzenesulfonyl chloride (99.4 mg, 0.328 mmol) sequentially at room temperature. The resulting solution was stirred at room temperature for 1 h before aqueous ammonium hydroxide (28%-30%, 8 mL) was added. The mixture was stirred at room temperature for 1 h before being evaporated. The residue was chromatographed (silica, CH_2Cl_2 -MeOH) to give the title compound (0.115 g, 99%) as a light yellow oil. ESIMS $m/z = 530.79 [\text{M}+\text{H}]^+$.

Example 14. Compound of Formula (I), wherein $\text{R}_1 = \text{R}_3 = \text{R}_{4a} = \text{R}_{4b} = \text{R}_{4c} = \text{H}$, $\text{R}_2 = \text{R}_{2a} = \text{F}$, $\text{R}_{3a} = \text{R}_5 = \text{OH}$, $\text{X} = \text{O}$, $\text{L} = \text{CH}_2$, $\text{B} = \text{cytosine-1-yl}$.


A solution of the compound of example 13 (0.115 g, 0.217 mmol) in anhydrous THF (6 mL) was treated with TBAF (1M in THF, 0.48 mL, 0.477 mmol) at room temperature for 30 min before being evaporated. The residue was chromatographed (silica, CH₂Cl₂-MeOH) to give the title compound (30.2 mg, 46%) as a white solid.

5 ESIMS $m/z = 302.22$ $[M+H]^+$.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without
10 departing from the scope of the invention encompassed by the appended claims.

WHAT IS CLAIMED IS:

1. A compound represented by Formula (I):



or its β -L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof, wherein:

X is selected from the group consisting of: O, S, Se, S(O), S(O)₂, CF₂, CHF, CH₂, C=CH₂, C=CHF, and C=CF₂;

R₁ is selected from the group consisting of:

- 1) hydrogen;
- 2) -CN;
- 3) halogen;
- 4) -N₃; and
- 5) substituted or unsubstituted -C₁-C₈ alkyl;

R₂, R_{2a}, R₃ and R_{3a} are each independently selected from the group consisting of:

- 1) -C₁-C₈ alkyl, -C₂-C₈ alkenyl, -C₂-C₈ alkynyl or -C₃-C₈ cycloalkyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;
- 2) substituted -C₁-C₈ alkyl, substituted -C₂-C₈ alkenyl, substituted -C₂-C₈ alkynyl or substituted -C₃-C₈ cycloalkyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;
- 3) aryl or substituted aryl;
- 4) heteroaryl or substituted heteroaryl;
- 5) heterocyclic or substituted heterocyclic;
- 6) hydrogen;
- 7) -CN;
- 8) -NO₂;

- 9) halogen;
- 10) $-N_3$; and
- 11) $-Y-R_{11}$, wherein Y is O, S, or NR_{12} ; and R_{11} and R_{12} are each independently selected from the group consisting of: hydrogen, hydroxy or amino protecting group, substituted or unsubstituted $-C_1-C_8$ alkyl, $-CN$, $-C(O)R_{14}$, $-C(O)OR_{13}$, and $-C(O)NR_{14}R_{14a}$; wherein R_{13} is selected from the group consisting of: substituted or unsubstituted $-C_1-C_{20}$ alkyl, substituted or unsubstituted $-C_2-C_{20}$ alkenyl, substituted or unsubstituted $-C_2-C_{20}$ alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclic or a group that is preferentially removed in a hepatocyte to yield the corresponding OH group; R_{14} is selected from the group consisting of: hydrogen and R_{13} ; and R_{14a} is selected from the group consisting of: hydrogen, hydroxy and R_{13} ; or alternatively R_{11} and R_{12} (in the case of $Y = NR_{12}$) or R_{14} and R_{14a} taken together with the nitrogen atom to which they are attached form a heterocyclic ring;

or alternatively R_2 and R_{2a} or R_3 and R_{3a} taken together with the carbon atom to which they are attached form a group selected from:

- 1) $C=O$;
- 2) $C=N-OR_{14}$;
- 3) $C=CR_{15}R_{16}$, wherein R_{15} and R_{16} are each independently selected from the group consisting of: hydrogen, halogen, and substituted or unsubstituted $-C_1-C_8$ alkyl;
- 4) substituted or unsubstituted C_3-C_8 cycloalkyl; and
- 5) 3-7 membered heterocyclic ring containing at least one heteroatom selected from O, S or N;

or alternatively R_2 and R_3 or R_{2a} and R_{3a} taken together with the carbon atoms to which they are attached and the bond connecting these two carbon atoms form a group selected from:

- 1) a double bond;
- 2) substituted or unsubstituted C_3-C_8 cycloalkyl ring; and
- 3) 3-7 membered heterocyclic ring containing at least one heteroatom selected from O, S, P or N;

alternatively R_1 and R_2 or R_1 and R_{2a} taken together with the two carbon atoms to which they are attached and the bond connecting these two carbon atoms form a group selected from:

- 5 1) a double bond;
- 2) substituted or unsubstituted C_3 - C_8 cycloalkyl ring; and
- 3) 3-7 membered heterocyclic ring containing at least one heteroatom selected from O, S or N;


- 10 R_{4a} , R_{4b} and R_{4c} are each independently selected from the group consisting of: hydrogen, halogen, and substituted or unsubstituted $-C_1$ - C_8 alkyl;

L is $-CH_2-$;

R_5 is $-Y-R_{11}$;

or alternatively L and R_5 taken together form a group of the following formula: $-L^1-$

- 15 $L^2-L^3-P(=Y^1)W^1W^2$; wherein Y^1 is O or S; L^1 is $-CR_{15}R_{16}-$ or absent; and one of L^2 and L^3 is absent or $-O-$, $-S-$, $-NH-$ or $-CR_{15}R_{16}-$, and the other is $-CR_{15}R_{16}-$; and W^1 and W^2 are each independently $-Y^4-R^x$, $-Y^5-R^y$ or a group of the formula:




wherein:

- 20 Y^2 at each occurrence is each independently O, S or NH;
- Y^3 at each occurrence is each independently absent, O, S, $-NR_{14}-$ or $-CR_{15}R_{16}-$;
- Y^4 and Y^5 at each occurrence are each independently absent, O, S, or $-NR_{14}-$;
- $M2$ is 0, 1 or 2;
- R^x and R^y at each occurrence are each independently R_{14} ; or alternatively R^x and
- 25 R^y taken together with the atoms to which they are attached form a heterocyclic ring or ring system;
- alternatively W^1 or W^2 and R_3 or R_{3a} taken together form a linker group selected from O, S, and $-NR_{14}-$; and

- 30 B is selected from the group consisting of: substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclic.

2. A compound of claim 1 represented by Formula (Ia):




5

or its β -L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof.

3. A compound of claim 1 represented by Formula (Ib):


10



or its β -L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof.



15

4. A compound of claim 1 represented by Formula (Ic):



or its β -L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof, wherein L^4 at each occurrence is independently absent or $-O-$, $-S-$, $-NH-$, or $-CR_{15}R_{16}-$.

5. A compound of claim 1, wherein B at each occurrence is an optionally substituted pyrimidinyl or purinyl group of formula (B1) or (B2):




wherein:

- R is selected from the group consisting of: O, S, NR_{14a} , $NC(O)R_{14a}$, $NC(O)OR_{14}$ and $NC(O)NR_{14}R_{14a}$;
- T, U, V and W are each independently N or CR_{17} ; wherein R_{17} is selected from the group consisting of: hydrogen, halogen, $-CN$, $-C(O)R_{14}$, $-C(O)NR_{14}R_{14a}$, $-NO_2$, $-N_3$, $-OR_{14}$, $-SR_{14}$, $-NR_{14}R_{14a}$, $-OC(O)R_{14}$, $-OC(O)OR_{14}$, $-NHC(O)R_{14a}$, $-NHC(O)OR_{14}$ and $-NHC(O)NR_{14}R_{14a}$,
- substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic, substituted or unsubstituted $-C_1-C_8$ alkyl, substituted or unsubstituted $-C_2-C_8$ alkenyl, substituted or unsubstituted $-C_2-C_8$ alkynyl;
- R^{20} , R^{21} and R^{22} are each independently selected from the group consisting of: hydrogen, halogen, $-CN$, $-C(O)R_{14}$, $-C(O)NR_{14}R_{14a}$, $-NO_2$, $-N_3$, $-OR_{14}$, $-SR_{14}$, $-NR_{14}R_{14a}$, $-OC(O)R_{14}$, $-OC(O)OR_{14}$, $-NHC(O)R_{14a}$, $-NHC(O)OR_{14}$ and $-NHC(O)NR_{14}R_{14a}$, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic, substituted or unsubstituted $-C_1-C_8$ alkyl, substituted or unsubstituted $-C_2-C_8$ alkenyl, substituted or unsubstituted $-C_2-C_8$ alkynyl.

6. A pharmaceutical composition comprising a compound or a combination of compounds according to claim 1 or a pharmaceutically acceptable salt, stereoisomer, tautomer, prodrug, salt of a prodrug, or combination thereof, in

combination with a pharmaceutically acceptable carrier or excipient.


7. The pharmaceutical composition of claim 6 further comprising a compound selected from the group consisting of cytokines, protease inhibitors, antiviral agents, proteases, immunomodulators, caspase inhibitors, antibodies and polymerase inhibitors.
8. A method of inhibiting the replication of an RNA or DNA-containing virus comprising contacting said virus with a therapeutically effective amount of a compound or combination of compounds of claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, prodrug, salt of a prodrug, or combination thereof.
9. A method of preventing or treating abnormal cellular proliferation, a viral infection, or a symptom thereof in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound or combination of compounds of claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, prodrug, salt of a prodrug, or combination thereof.
10. The method of claim 8 wherein the virus is human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV).
11. A process for preparing the compound of claim 1, comprising the step of:
 - (a) reacting a nucleoside derivative represented by formulae (1-1), (1-1a), (1-2) or (1-2a):



wherein PG is a hydroxy protecting group, and LG is a leaving group, with a base or a transition metal compound or combination of transition metal compounds;

optionally in the presence of a nucleophile of formula $R_{4b}\text{-M-LG}$ or $R_{4a}\text{-M-LG}$ wherein M is a metal such as Mg; and optionally in the presence of a salt; or

(b) reacting a compound of the formula



5 wherein R_4 is -C_{1-8} alkyl or -C(O)-C_{1-8} alkyl, with an acid or a Lewis acid in the presence of an alkyne.

12. A compound of claim 1, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof, wherein the compound is selected from the group consisting of:
- 10 Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = \text{H}$, $R_{2a} = R_{3a} = R_5 = \text{OTBS}$, $X = \text{O}$, $L = \text{CH}_2$, $B = 3\text{-methoxycarbonyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl}$;
- Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = \text{H}$, $R_{2a} = R_{3a} = R_5 = \text{OTBS}$, $X = \text{O}$, $L = \text{CH}_2$, $B = \text{uracil-1-yl}$;
- 15 Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = \text{H}$, $R_{2a} = R_{3a} = R_5 = \text{OTBS}$, $X = \text{O}$, $L = \text{CH}_2$, $B = \text{cytosine-1-yl}$;
- Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = \text{H}$, $R_{2a} = R_{3a} = R_5 = \text{OH}$, $X = \text{O}$, $L = \text{CH}_2$, $B = \text{cytosine-1-yl}$;
- 20 Compound of Formula (I), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = \text{H}$, $R_{2a} = R_{3a} = R_5 = \text{OH}$, $X = \text{O}$, $L = \text{CH}_2$, $B = \text{uracil-1-yl}$;
- Compound of Formula (Ib), wherein $R_1 = R_2 = R_3 = R_{4a} = R_{4b} = R_{4c} = \text{H}$, $R_{2a} = R_{3a} = \text{OH}$, $R_5 = \text{-OP(O)(OPh)(NHCHMeCO}_2\text{Me)}$, $X = \text{O}$, $L = \text{CH}_2$, $B = \text{uracil-1-yl}$;
- 25 Compound of Formula (I), wherein $R_1 = R_{2a} = R_3 = R_{4a} = R_{4b} = R_{4c} = \text{H}$, $R_2 = \text{F}$, $R_{3a} = R_5 = \text{OTBS}$, $X = \text{O}$, $L = \text{CH}_2$, $B = 3\text{-methoxycarbonyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl}$;
- Compound of Formula (I), wherein $R_1 = R_{2a} = R_3 = R_{4a} = R_{4b} = R_{4c} = \text{H}$, $R_2 = \text{F}$, $R_{3a} = R_5 = \text{OTBS}$, $X = \text{O}$, $L = \text{CH}_2$, $B = \text{uracil-1-yl}$;

Compound of Formula (I), wherein $R_1 = R_{2a} = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = F$, $R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = \text{cytosine-1-yl}$;

Compound of Formula (I), wherein $R_1 = R_{2a} = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = F$, $R_{3a} = R_5 = OH$, $X = O$, $L = CH_2$, $B = \text{cytosine-1-yl}$;

- 5 Compound of Formula (I), wherein $R_1 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = R_{2a} = F$, $R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = 3\text{-methoxycarbonyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl}$;

Compound of Formula (I), wherein $R_1 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = R_{2a} = F$, $R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = \text{uracil-1-yl}$;

- 10 Compound of Formula (I), wherein $R_1 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = R_{2a} = F$, $R_{3a} = R_5 = OTBS$, $X = O$, $L = CH_2$, $B = \text{cytosine-1-yl}$; and

Compound of Formula (I), wherein $R_1 = R_3 = R_{4a} = R_{4b} = R_{4c} = H$, $R_2 = R_{2a} = F$, $R_{3a} = R_5 = OH$, $X = O$, $L = CH_2$, $B = \text{cytosine-1-yl}$.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 09/56631

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07D 501/00 (2009.01)

USPC - 514/274

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC (8): C07D 501/00 (2009.01)

USPC: 514/274

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

IPC (8): C07D 501/00 (2009.01) (See keywords below)

USPC: 514/274 ; 514/265 ; 514/266 ; 544/276 ; 544/277 ; 544/313 ; 435/6 (See keywords below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST: DB=PGPB,USPT,USOC,EPAB,JPAB : Google: Scholar/patents: allenic Phosphate Esters Nucleoside Phosphonates alkenyl

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 7,247,621 B2 (HONG et al) 24 July 2007 (24.07.2007) Col 8, In 20-66; Col 9, In 27-30 ; Col 10, In 1-24; Col 19, In 49-57; Col 20, In 8-18; Col 21, In 33-36; Col 21, In 53-66	1-12
Y	US 5, 750,806 A (BROCKER et al) 12 May 1998 (12.05.1998) Col 1, In 5-10; Col 2, In 13-20	11
Y	HAYASHI et al. Adenallene and Cytallene: Acyclic Nucleoside Analogues That Inhibit Replication and Cytopathic Effect of Human Immunodeficiency Virus In Vitro, Proceedings of the National Academy of Science USA, August 1988, Vol 85, pp 6127-6131. pg 6128, Figure 1; pg 6128, Table 1; pg 6129, Figure 2	1-12

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
25 November 2009 (25.11.2009)

Date of mailing of the international search report

07 DEC 2009

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774